[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fetpCTYJ6VE_bZQIkCNKbBJjMcUpJKIgePu5MN2gZxgY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",[4],535,false,63,72,231710,33,302,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Obesity",88,{"name":18,"count":19},"Diabetes",26,{"name":21,"count":22},"Healthy Volunteers",19,{"name":24,"count":25},"Diabetes Mellitus",18,{"name":27,"count":25},"Diabetes Mellitus, Type 2",{"name":29,"count":30},"Overweight",13,{"name":32,"count":30},"Type 2 Diabetes",{"name":34,"count":35},"Lipodystrophy",12,[37,42,47,52,57,62,67,71,74,79],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT00085982","Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance","2019-10-23","Metreleptin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05743244","Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)","2026-06-30","Abrocitinib 200 MG Oral",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04862221","TReatment for ImmUne Mediated PathopHysiology","2026-08","High-dose methylprednisolone",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03884075","Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)","2026-08-31","Semaglutide",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03049462","The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","2026-09-30","Mirabegron",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03929601","Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","2027-03-31","Rituximab-pvvr",{"nctId":68,"briefTitle":69,"date":70,"intervention":41},"NCT02262806","Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy","2027-07-31",{"nctId":72,"briefTitle":73,"date":70,"intervention":41},"NCT02262832","Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT00977977","Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","2027-12-31","Rituximab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05470504","Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance","2028-01-30","Pegvisomant",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,121,177,208,241,277,332,374,396,436,464,499,523,555,581,604,626,644,662,687,717,735,753,771,789,812,830,848,866,887,905,928,952,979,1066,1124,1161,1197,1222,1240,1265,1283,1301,1319,1343,1365,1410,1443,1472,1494,1529,1564,1589,1607,1634,1659,1677,1705,1723,1749,1774,1799,1817,1842,1867,1891,1916,1942,1966,1984,2010,2038,2056,2082,2108,2126,2150,2177,2204,2222,2246,2269,2292,2316,2340,2369,2387,2405,2431,2456,2481,2506,2524,2549,2573,2597,2622,2645,2663,2686,2710,2734,2763,2781,2799,2817,2835,2885,2929,2973,3008,3036,3073,3095,3116,3134,3159,3181,3208,3226,3246,3269,3292,3316,3343,3367,3391,3413,3436,3460,3483,3501,3524,3548,3573,3598,3622,3640,3661,3686,3713,3731,3755,3773,3800,3818,3841,3859,3877,3898,3921,3944,3970,3988,4010,4036,4054,4072,4090,4108,4126,4148,4173,4201,4219,4237,4255,4279,4297,4321,4346,4364,4386,4404,4422,4449,4467,4485,4509,4531,4549,4567,4592,4610,4632,4657,4691,4709,4727,4745,4763,4781,4799,4817,4835,4853,4876,4894,4918,4941,4968,4986,5004,5022,5048,5072,5090,5112,5137,5162,5180,5198,5216,5244,5266,5290,5308,5331,5354,5372,5395,5413,5435,5459,5484,5507,5529,5553,5575,5599,5623,5647,5670,5694,5715,5740,5763,5785,5806,5830,5855,5873,5898,5921,5942,5964,5989,6007,6030,6052,6124,6174,6220,6245,6267,6285,6303,6325,6343,6361,6383,6406,6429,6453,6476,6499,6522,6544,6567,6589,6615,6633,6655,6678,6701,6722],{"intervention":93,"totalTrials":94,"cells":95},"Epclusa",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":119},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":118},"NCT03520660","People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","ACTIVE_NOT_RECRUITING",[89],"2032-12-31","2018-10-19",121,[24,116,117],"Hepatitis C, Chronic","Cardiovascular Diseases",[93],{"trials":120,"activeCount":98},[],{"intervention":41,"totalTrials":122,"cells":123},5,{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":165,"PHASE4":173,"NA":175},{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":98},[],{"trials":129,"activeCount":164,"soonestReadout":40},[130,137,145,155],{"nctId":68,"briefTitle":69,"status":110,"phases":131,"primaryCompletion":70,"completion":70,"start":132,"enrollment":133,"conditions":134,"interventions":136},[87],"2014-10-14",29,[18,34,135],"Hyperlipidemia",[41],{"nctId":38,"briefTitle":39,"status":110,"phases":138,"primaryCompletion":40,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},[87],"2030-01-01","2003-08-21",11,[143],"Severe Insulin Resistance",[41],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT00025883","Leptin to Treat Lipodystrophy","COMPLETED",[87],"2015-02","2001-10",103,[34],[41],{"nctId":156,"briefTitle":157,"status":148,"phases":158,"primaryCompletion":159,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT01778556","Short-term Effects of Leptin in People With Lipodystrophy",[87],"2018-02-23","2013-01-26",25,[34],[41],2,{"trials":166,"activeCount":94,"soonestReadout":70},[167],{"nctId":72,"briefTitle":73,"status":110,"phases":168,"primaryCompletion":70,"completion":70,"start":169,"enrollment":170,"conditions":171,"interventions":172},[88],"2014-10-09",24,[34,18,135],[41],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"intervention":178,"totalTrials":94,"cells":179},"18F-FCH",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":204,"NA":206},{"trials":181,"activeCount":98},[],{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":94,"soonestReadout":193},[188],{"nctId":189,"briefTitle":190,"status":191,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":203},"NCT07444723","Accuracy of 18F-Fluorocholine PET\u002FMR and NeuroEXPLORER PET\u002FCT Imaging for Localization of Parathyroid Tumors","RECRUITING",[87,88],"2035-02-05","2036-02-05","2026-04-16",193,[198,199,200,201,202],"Primary Hyperparathyroidism","Parathyroid Cancer","Multiple Endocrine Neoplasias","Heritable Hyperparathyroidism","Hyperparathyroid-jaw Tumor Syndrome",[178],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":98},[],{"intervention":61,"totalTrials":164,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":221,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":94,"soonestReadout":60},[214],{"nctId":58,"briefTitle":59,"status":191,"phases":215,"primaryCompletion":60,"completion":60,"start":216,"enrollment":217,"conditions":218,"interventions":220},[86],"2017-03-13",100,[219],"Polycystic Ovary Syndrome",[61],{"trials":222,"activeCount":94,"soonestReadout":228},[223],{"nctId":224,"briefTitle":225,"status":226,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT05713799","Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity","NOT_YET_RECRUITING",[87],"2030-03-01","2026-06-07",60,[232,15],"Insulin Resistance",[234,61],"Alpha-lipoic acid",{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":98},[],{"intervention":242,"totalTrials":164,"cells":243},"Thyrogen",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":260,"PHASE4":262,"NA":275},{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":98},[],{"trials":249,"activeCount":94,"soonestReadout":254},[250],{"nctId":251,"briefTitle":252,"status":191,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT03841617","The Use of 124-I-PET\u002FCT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer",[87],"2035-11-01","2019-07-29",30,[258],"Thyroid Cancer",[242],{"trials":261,"activeCount":98},[],{"trials":263,"activeCount":98},[264],{"nctId":265,"briefTitle":266,"status":148,"phases":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":274},"NCT00001730","Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.",[89],"2000-04","1997-12",20,[272,273],"Hypothyroidism","Thyroid Neoplasms",[242],{"trials":276,"activeCount":98},[],{"intervention":278,"totalTrials":279,"cells":280},"Dexamethasone",3,{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":326,"PHASE4":328,"NA":330},{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":94,"soonestReadout":301},[287,297,309],{"nctId":288,"briefTitle":289,"status":148,"phases":290,"completion":291,"start":292,"enrollment":270,"conditions":293,"interventions":296},"NCT00004990","Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis",[87],"2004-12","2000-03",[294,295],"Glomerulonephritis","Nephrotic Syndrome",[278],{"nctId":298,"briefTitle":299,"status":191,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT06635629","Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome",[87],"2028-10-01","2029-01-01","2024-12-12",140,[306],"Cushing Syndrome",[308,278],"Desmopressin",{"nctId":310,"briefTitle":311,"status":148,"phases":312,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":322},"NCT01294319","Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men",[87],"2016-08-10","2011-01-24",51,[317,318,319,320,321],"Cortisol Resistance","Negative Feedback","ACTH","Mineralcorticoid","Glucocorticoid",[323,324,325,278],"Mifepristone","Spironolactone","Combined",{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":98},[],{"intervention":333,"totalTrials":164,"cells":334},"68Ga-DOTATATE",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":336,"activeCount":98},[],{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":94,"soonestReadout":345},[341,352],{"nctId":342,"briefTitle":343,"status":191,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT02019706","Prospective Evaluation of 68Ga-DOTATATE PET\u002FCT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome",[87],"2030-12-31","2014-02-12",80,[319,349],"Cushing's Syndrome",[333,351],"18F-DOPA",{"nctId":353,"briefTitle":354,"status":148,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":366},"NCT00001277","Studies of Elevated Parathyroid Activity",[87],"2020-03-11","2020-12-23","1993-12-15",1553,[361,362,363,364,365],"Hyperparathyroidism","Hypercalcemia","Parathyroid Neoplasm","Multiple Endocrine Neoplasia","MEN1",[367,351],"68Ga-Dotatate",{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"intervention":351,"totalTrials":164,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":94,"soonestReadout":345},[382,386],{"nctId":342,"briefTitle":343,"status":191,"phases":383,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":384,"interventions":385},[87],[319,349],[333,351],{"nctId":353,"briefTitle":354,"status":148,"phases":387,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":388,"interventions":389},[87],[361,362,363,364,365],[367,351],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"intervention":397,"totalTrials":164,"cells":398},"Teplizumab",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":400,"activeCount":98},[],{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":94,"soonestReadout":423},[405,419],{"nctId":406,"briefTitle":407,"status":148,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":418},"NCT01030861","Teplizumab for Prevention of Type 1 Diabetes In Relatives \"At-Risk\"",[87],"2018-11","2019-06","2010-08",76,[414,415,416,417],"Autoantibody Positive","Non-diabetic Relatives at Risk for Type 1 Diabetes","High Risk","Impaired Glucose Tolerance",[397],{"nctId":420,"briefTitle":421,"status":226,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":230,"conditions":426,"interventions":428},"NCT07216391","Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG",[87],"2029-11-30","2030-05-30","2026-07-30",[427],"Type 1 Diabetes Mellitus",[429,397],"Antithymocyte Globulin",{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"intervention":429,"totalTrials":164,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":94,"soonestReadout":423},[444,454],{"nctId":445,"briefTitle":446,"status":447,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":164,"conditions":451,"interventions":453},"NCT04291703","STOP-T1D Low-Dose (ATG)","TERMINATED",[87],"2024-12-17","2023-11-01",[452],"Diabetes Mellitus, Type 1",[429],{"nctId":420,"briefTitle":421,"status":226,"phases":455,"primaryCompletion":423,"completion":424,"start":425,"enrollment":230,"conditions":456,"interventions":457},[87],[427],[429,397],{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"intervention":465,"totalTrials":164,"cells":466},"rituximab",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":468,"activeCount":98},[],{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":94,"soonestReadout":77},[473,483],{"nctId":474,"briefTitle":475,"status":476,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":98,"conditions":480,"interventions":482},"NCT00550342","Rituximab Treatment of Focal Segmental Glomerulosclerosis","WITHDRAWN",[87],"2009-12","2008-01",[481],"Focal Segmental Glomerulosclerosis (FSGS)",[465],{"nctId":75,"briefTitle":76,"status":191,"phases":484,"primaryCompletion":77,"completion":77,"start":485,"enrollment":256,"conditions":486,"interventions":491},[87],"2010-12-22",[295,487,488,489,490],"Proteinuria","Autoimmune Disease","Glomerular Disease","Membranous Glomerulonephritis",[78,492],"Oral Cyclosporine",{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":98},[],{"trials":498,"activeCount":98},[],{"intervention":500,"totalTrials":94,"cells":501},"Rezpegaldesleukin",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":503,"activeCount":98},[],{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":94,"soonestReadout":512},[508],{"nctId":509,"briefTitle":510,"status":191,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT07142252","Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus",[87],"2028-05-25","2026-03-25",66,[427],[500],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"intervention":524,"totalTrials":94,"cells":525},"Rosuvastatin",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":94,"soonestReadout":536},[532],{"nctId":533,"briefTitle":534,"status":191,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":548},"NCT05832229","Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States",[87],"2029-08-31","2023-12-07",256,[540,541,542,543,544,545,546,547],"Cirrhosis","Cirrhosis, Liver","Cirrhosis Early","Cirrhosis Due to Hepatitis B","Cirrhosis Advanced","Cirrhosis Infectious","Cirrhosis Alcoholic","Cirrhosis Due to Hepatitis C",[524],{"trials":550,"activeCount":98},[],{"trials":552,"activeCount":98},[],{"trials":554,"activeCount":98},[],{"intervention":556,"totalTrials":94,"cells":557},"VIR-2218 and peginterferon alfa-2a",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":94,"soonestReadout":568},[564],{"nctId":565,"briefTitle":566,"status":191,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT06092333","VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B",[87],"2028-02-29","2028-08-31","2025-01-31",50,[573],"Chronic Hepatitis B",[556],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"trials":580,"activeCount":98},[],{"intervention":582,"totalTrials":94,"cells":583},"177Lu-DOTA-EB-TATE",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":98},[],{"trials":589,"activeCount":94,"soonestReadout":594},[590],{"nctId":591,"briefTitle":592,"status":226,"phases":593,"primaryCompletion":594,"completion":595,"start":229,"enrollment":25,"conditions":596,"interventions":597},"NCT06991738","177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer",[86,87],"2032-07-01","2032-08-01",[258],[582],{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[],{"trials":603,"activeCount":98},[],{"intervention":46,"totalTrials":94,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":94,"soonestReadout":45},[612],{"nctId":43,"briefTitle":44,"status":110,"phases":613,"primaryCompletion":45,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":618},[87],"2027-06-30","2023-10-19",78,[452],[46,619],"Ritlecitinib",{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"trials":625,"activeCount":98},[],{"intervention":619,"totalTrials":94,"cells":627},{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":94,"soonestReadout":45},[634],{"nctId":43,"briefTitle":44,"status":110,"phases":635,"primaryCompletion":45,"completion":614,"start":615,"enrollment":616,"conditions":636,"interventions":637},[87],[452],[46,619],{"trials":639,"activeCount":98},[],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"intervention":234,"totalTrials":94,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":647,"activeCount":98},[],{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":94,"soonestReadout":228},[652],{"nctId":224,"briefTitle":225,"status":226,"phases":653,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":654,"interventions":655},[87],[232,15],[234,61],{"trials":657,"activeCount":98},[],{"trials":659,"activeCount":98},[],{"trials":661,"activeCount":98},[],{"intervention":663,"totalTrials":94,"cells":664},"68-Gallium-DOTATATE-PET\u002FCT",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":94,"soonestReadout":675},[671],{"nctId":672,"briefTitle":673,"status":191,"phases":674,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":680},"NCT04927416","The Role of 68-Gallium-DOTATATE-PET\u002FCT in the Imaging of Metastatic Thyroid Cancer",[87],"2030-11-30","2021-10-25",54,[679],"Metastic Thyroid Cancer",[663],{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[],{"trials":686,"activeCount":98},[],{"intervention":51,"totalTrials":94,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":94,"soonestReadout":50},[695],{"nctId":48,"briefTitle":49,"status":191,"phases":696,"primaryCompletion":50,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":706},[87],"2027-02","2022-02-09",163,[701,702,703,704,705],"Acute Liver Failure","Fulminant Hepatic Failure","Hepatic Encephalopathy","Acute Liver Injury","Immune Dysregulation",[51,707,708,709,710],"Equine anti-thymocyte globulin","Prednisolone","Diphenhydramine","Methylprednisolone",{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"intervention":707,"totalTrials":94,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":94,"soonestReadout":50},[725],{"nctId":48,"briefTitle":49,"status":191,"phases":726,"primaryCompletion":50,"completion":697,"start":698,"enrollment":699,"conditions":727,"interventions":728},[87],[701,702,703,704,705],[51,707,708,709,710],{"trials":730,"activeCount":98},[],{"trials":732,"activeCount":98},[],{"trials":734,"activeCount":98},[],{"intervention":708,"totalTrials":94,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":738,"activeCount":98},[],{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":94,"soonestReadout":50},[743],{"nctId":48,"briefTitle":49,"status":191,"phases":744,"primaryCompletion":50,"completion":697,"start":698,"enrollment":699,"conditions":745,"interventions":746},[87],[701,702,703,704,705],[51,707,708,709,710],{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":98},[],{"intervention":709,"totalTrials":94,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":94,"soonestReadout":50},[761],{"nctId":48,"briefTitle":49,"status":191,"phases":762,"primaryCompletion":50,"completion":697,"start":698,"enrollment":699,"conditions":763,"interventions":764},[87],[701,702,703,704,705],[51,707,708,709,710],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"intervention":710,"totalTrials":94,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":94,"soonestReadout":50},[779],{"nctId":48,"briefTitle":49,"status":191,"phases":780,"primaryCompletion":50,"completion":697,"start":698,"enrollment":699,"conditions":781,"interventions":782},[87],[701,702,703,704,705],[51,707,708,709,710],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"intervention":66,"totalTrials":94,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":94,"soonestReadout":65},[797],{"nctId":63,"briefTitle":64,"status":110,"phases":798,"primaryCompletion":65,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":803},[87],"2029-03-31","2023-10-30",74,[427],[66,804,805],"Abatacept","Sterile Sodium Chloride",{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"intervention":804,"totalTrials":94,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":98},[],{"trials":819,"activeCount":94,"soonestReadout":65},[820],{"nctId":63,"briefTitle":64,"status":110,"phases":821,"primaryCompletion":65,"completion":799,"start":800,"enrollment":801,"conditions":822,"interventions":823},[87],[427],[66,804,805],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":98},[],{"trials":829,"activeCount":98},[],{"intervention":805,"totalTrials":94,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":94,"soonestReadout":65},[838],{"nctId":63,"briefTitle":64,"status":110,"phases":839,"primaryCompletion":65,"completion":799,"start":800,"enrollment":801,"conditions":840,"interventions":841},[87],[427],[66,804,805],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"intervention":308,"totalTrials":94,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":94,"soonestReadout":301},[856],{"nctId":298,"briefTitle":299,"status":191,"phases":857,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":858,"interventions":859},[87],[306],[308,278],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":881,"PHASE4":883,"NA":885},{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":94,"soonestReadout":82},[874],{"nctId":80,"briefTitle":81,"status":191,"phases":875,"primaryCompletion":82,"completion":82,"start":876,"enrollment":161,"conditions":877,"interventions":880},[87],"2023-01-23",[878,879],"Insulin Receptor Mutation","Partial Lipodystrophy",[83],{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[],{"intervention":492,"totalTrials":94,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":94,"soonestReadout":77},[895],{"nctId":75,"briefTitle":76,"status":191,"phases":896,"primaryCompletion":77,"completion":77,"start":485,"enrollment":256,"conditions":897,"interventions":898},[87],[295,487,488,489,490],[78,492],{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":98},[],{"trials":904,"activeCount":98},[],{"intervention":56,"totalTrials":94,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":94,"soonestReadout":55},[913],{"nctId":53,"briefTitle":54,"status":191,"phases":914,"primaryCompletion":55,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":921},[87],"2026-10-02","2019-07-24",84,[919,920],"Non-Alcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease",[56],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"intervention":929,"totalTrials":94,"cells":930},"[18F]-DOPA",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":939,"NA":941},{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":94},[943],{"nctId":944,"briefTitle":945,"status":191,"phases":946,"start":947,"enrollment":948,"conditions":949,"interventions":951},"NCT00646022","Natural History of Familial Carcinoid Tumor",[],"2008-08-25",1600,[950],"Carcinoid",[929],{"intervention":953,"totalTrials":94,"cells":954},"68-Gallium Dotatate",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"trials":964,"activeCount":98},[],{"trials":966,"activeCount":94},[967],{"nctId":968,"briefTitle":969,"status":191,"phases":970,"start":971,"enrollment":972,"conditions":973,"interventions":978},"NCT00001160","Studies on Tumors of the Thyroid",[],"1977-06-01",2500,[974,975,976,258,977],"Hurthle Cell Thyroid Cancer","Tall Cell Variant Thyroid Cancer","Follicular Thyroid Cancer","Papillary Thyroid Cancer",[953],{"intervention":980,"totalTrials":981,"cells":982},"Ribavirin",7,{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":1019,"PHASE4":1043,"NA":1064},{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[989,1000,1009],{"nctId":990,"briefTitle":991,"status":148,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT00735969","High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1",[87],"2013-06","2008-08",21,[997],"Chronic Hepatitis C",[999,980],"Peginterferon",{"nctId":1001,"briefTitle":1002,"status":148,"phases":1003,"primaryCompletion":1004,"completion":1005,"start":1004,"enrollment":170,"conditions":1006,"interventions":1007},"NCT02118012","Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C",[86,87],"2014-03-20","2016-09-20",[997],[1008,980],"Chlorcyclizine HCl",{"nctId":1010,"briefTitle":1011,"status":148,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":170,"conditions":1015,"interventions":1016},"NCT00475176","S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C",[87],"2011-05","2007-05",[997],[1017,980,1018],"Peginterferon alfa-2a","S-adenosyl methionine for Chronic Liver Disease",{"trials":1020,"activeCount":98},[1021,1032],{"nctId":1022,"briefTitle":1023,"status":148,"phases":1024,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1031},"NCT00001729","Combination Drug Therapy for Patients With Hepatitis C",[88],"2002-09","1997-10",120,[997,1029,1030],"Fibrosis","Hemolytic Anemia",[980],{"nctId":1033,"briefTitle":1034,"status":148,"phases":1035,"primaryCompletion":291,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT00038974","Hepatitis C Antiviral Resistance in African-Americans",[88],"2005-11","2002-08",401,[1040],"Hepatitis C",[1042,980],"peginterferon alfa-2a",{"trials":1044,"activeCount":98},[1045,1055],{"nctId":1046,"briefTitle":1047,"status":148,"phases":1048,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1054},"NCT00056862","Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3",[89],"2010-01","2010-06","2003-03",58,[1040],[1017,1017,980],{"nctId":1056,"briefTitle":1057,"status":148,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":571,"conditions":1062,"interventions":1063},"NCT00001854","Long-Term Therapy With Ribavirin for Chronic Hepatitis C",[89],"2007-10-10","2008-01-15","1999-02-12",[997],[980],{"trials":1065,"activeCount":98},[],{"intervention":1017,"totalTrials":1067,"cells":1068},6,{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1088,"PHASE4":1108,"NA":1122},{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[1075,1084],{"nctId":1076,"briefTitle":1077,"status":148,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1083},"NCT02364336","Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment",[87],"2018-05-21","2015-02-14",14,[573],[1017],{"nctId":1010,"briefTitle":1011,"status":148,"phases":1085,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":170,"conditions":1086,"interventions":1087},[87],[997],[1017,980,1018],{"trials":1089,"activeCount":98},[1090,1104],{"nctId":1091,"briefTitle":1092,"status":148,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1102},"NCT00006164","Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment",[88],"2007-04","2009-10","2000-06",1050,[1099,541,1100,1101],"Chronic Hepatitis c","Fibrosis, Liver","Hepatic Cirrhosis",[1103,1017],"Peginterferon alfa-2a + Ribavirin",{"nctId":1033,"briefTitle":1034,"status":148,"phases":1105,"primaryCompletion":291,"completion":1036,"start":1037,"enrollment":1038,"conditions":1106,"interventions":1107},[88],[1040],[1042,980],{"trials":1109,"activeCount":98},[1110,1118],{"nctId":1111,"briefTitle":1112,"status":148,"phases":1113,"primaryCompletion":1050,"completion":1050,"start":1114,"enrollment":571,"conditions":1115,"interventions":1116},"NCT00028093","Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease",[89],"2001-12",[997],[1117,1017],"Peginterferon alfa-2a with Ribavirin",{"nctId":1046,"briefTitle":1047,"status":148,"phases":1119,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":1120,"interventions":1121},[89],[1040],[1017,1017,980],{"trials":1123,"activeCount":98},[],{"intervention":1125,"totalTrials":164,"cells":1126},"Lamivudine",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1143,"PHASE4":1145,"NA":1159},{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":98},[],{"trials":1132,"activeCount":98},[1133],{"nctId":1134,"briefTitle":1135,"status":148,"phases":1136,"completion":1137,"start":1138,"enrollment":230,"conditions":1139,"interventions":1142},"NCT00001457","Lamivudine for Chronic Hepatitis B",[87],"2005-09","1995-09",[573,1140,294,1141],"Chronic Hepatitis D","Polyarteritis Nodosa",[1125],{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[1147],{"nctId":1148,"briefTitle":1149,"status":148,"phases":1150,"completion":1151,"start":1152,"conditions":1153,"interventions":1155},"NCT00006190","A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy",[89],"2001-11","2000-11",[1154,34],"HIV Infections",[1156,1157,1125,1158],"Nelfinavir mesylate","Stavudine","Efavirenz",{"trials":1160,"activeCount":98},[],{"intervention":1162,"totalTrials":164,"cells":1163},"sertraline",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1181,"PHASE4":1183,"NA":1195},{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[],{"trials":1169,"activeCount":98},[1170],{"nctId":1171,"briefTitle":1172,"status":148,"phases":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1180},"NCT00058903","Treatment of Cholestatic Pruritus With Sertraline",[87],"2005-03","2003-04",40,[1178,1179,1040],"Pruritus","Liver Cirrhosis, Biliary",[1162],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[1185],{"nctId":1186,"briefTitle":1187,"status":148,"phases":1188,"completion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT00374426","Preventing Depression Recurrence in Diabetes",[89],"2004-10","1998-03",262,[1193,18],"Major Depression",[1162],{"trials":1196,"activeCount":98},[],{"intervention":1198,"totalTrials":94,"cells":1199},"orlistat",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1220},{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":98},[],{"trials":1205,"activeCount":98},[],{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[1210],{"nctId":1211,"briefTitle":1212,"status":148,"phases":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1219},"NCT00212199","Effectiveness of Brief Counseling for Weight Management",[89],"2004-08","2002-01",246,[1218],"1. Obesity",[1198],{"trials":1221,"activeCount":98},[],{"intervention":1117,"totalTrials":94,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1238},{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[1234],{"nctId":1111,"briefTitle":1112,"status":148,"phases":1235,"primaryCompletion":1050,"completion":1050,"start":1114,"enrollment":571,"conditions":1236,"interventions":1237},[89],[997],[1117,1017],{"trials":1239,"activeCount":98},[],{"intervention":1241,"totalTrials":94,"cells":1242},"nateglinide",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1263},{"trials":1244,"activeCount":98},[],{"trials":1246,"activeCount":98},[],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[1253],{"nctId":1254,"briefTitle":1255,"status":148,"phases":1256,"completion":1257,"start":1258,"enrollment":304,"conditions":1259,"interventions":1261},"NCT00212290","Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes",[89],"2006-12","2002-11",[232,1260],"Type 2 Diabetes Mellitus",[1262,1241],"pioglitazone",{"trials":1264,"activeCount":98},[],{"intervention":1156,"totalTrials":94,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1281},{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[],{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[1277],{"nctId":1148,"briefTitle":1149,"status":148,"phases":1278,"completion":1151,"start":1152,"conditions":1279,"interventions":1280},[89],[1154,34],[1156,1157,1125,1158],{"trials":1282,"activeCount":98},[],{"intervention":1157,"totalTrials":94,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1293,"NA":1299},{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[1295],{"nctId":1148,"briefTitle":1149,"status":148,"phases":1296,"completion":1151,"start":1152,"conditions":1297,"interventions":1298},[89],[1154,34],[1156,1157,1125,1158],{"trials":1300,"activeCount":98},[],{"intervention":1158,"totalTrials":94,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1309,"PHASE4":1311,"NA":1317},{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[1313],{"nctId":1148,"briefTitle":1149,"status":148,"phases":1314,"completion":1151,"start":1152,"conditions":1315,"interventions":1316},[89],[1154,34],[1156,1157,1125,1158],{"trials":1318,"activeCount":98},[],{"intervention":1320,"totalTrials":94,"cells":1321},"oxandrolone",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1341},{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":98},[1332],{"nctId":1333,"briefTitle":1334,"status":148,"phases":1335,"completion":1336,"start":1337,"conditions":1338,"interventions":1340},"NCT00006167","Nutrition Intervention in AIDS Wasting",[89],"2000-08","1998-01",[1339],"HIV Wasting Syndrome",[1320],{"trials":1342,"activeCount":98},[],{"intervention":1344,"totalTrials":94,"cells":1345},"Salsalate",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1363},{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[1356],{"nctId":1357,"briefTitle":1358,"status":148,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1051,"enrollment":677,"conditions":1361,"interventions":1362},"NCT00339833","The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers",[89],"2008-07",[32,18],[1344],{"trials":1364,"activeCount":98},[],{"intervention":1366,"totalTrials":279,"cells":1367},"Lisinopril",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1406,"NA":1408},{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[1376,1388,1399],{"nctId":1377,"briefTitle":1378,"status":148,"phases":1379,"primaryCompletion":1380,"completion":1380,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1385},"NCT00004266","Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes",[88],"1999-07","1993-08",160,[1384],"Diabetic Nephropathy",[1366,1386,1387],"Nifedipine","Simvastatin",{"nctId":1389,"briefTitle":1390,"status":148,"phases":1391,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1397},"NCT01885559","HALT Progression of Polycystic Kidney Disease Study B",[88],"2014-06","2006-01",486,[1396],"Kidney, Polycystic",[1366,1398],"Telmisartan",{"nctId":1400,"briefTitle":1401,"status":148,"phases":1402,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT00283686","HALT Progression of Polycystic Kidney Disease Study A",[88],558,[1396],[1366,1398],{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"intervention":1411,"totalTrials":164,"cells":1412},"Entecavir and peginterferon",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1439,"NA":1441},{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[1421,1430],{"nctId":1422,"briefTitle":1423,"status":148,"phases":1424,"primaryCompletion":1425,"completion":1425,"start":1426,"enrollment":230,"conditions":1427,"interventions":1429},"NCT01368497","Entecavir\u002FPegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection",[88],"2016-12-23","2012-09",[1428],"Hepatitis B",[1411],{"nctId":1431,"briefTitle":1432,"status":447,"phases":1433,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1438},"NCT01369199","Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B",[88],"2017-02-14","2012-05",28,[1428],[1411],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"intervention":1386,"totalTrials":164,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1460,"PHASE3":1462,"PHASE4":1468,"NA":1470},{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[1449],{"nctId":1450,"briefTitle":1451,"status":148,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1067,"conditions":1455,"interventions":1459},"NCT00712738","Oral Nifedipine to Treat Iron Overload",[86],"2010-09-22","2008-06-20",[1456,1457,1458],"Thalassemia","Iron Overload","Hemochromatosis",[1386],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[1464],{"nctId":1377,"briefTitle":1378,"status":148,"phases":1465,"primaryCompletion":1380,"completion":1380,"start":1381,"enrollment":1382,"conditions":1466,"interventions":1467},[88],[1384],[1366,1386,1387],{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":98},[],{"intervention":1398,"totalTrials":164,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1490,"NA":1492},{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[1482,1486],{"nctId":1389,"briefTitle":1390,"status":148,"phases":1483,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1394,"conditions":1484,"interventions":1485},[88],[1396],[1366,1398],{"nctId":1400,"briefTitle":1401,"status":148,"phases":1487,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1403,"conditions":1488,"interventions":1489},[88],[1396],[1366,1398],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"intervention":1495,"totalTrials":164,"cells":1496},"Oral Insulin",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1525,"NA":1527},{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[1505,1515],{"nctId":1506,"briefTitle":1507,"status":148,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1514},"NCT00419562","Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus",[88],"2016-12","2017-06","2007-02",560,[452],[1495],{"nctId":1516,"briefTitle":1517,"status":148,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT00004984","The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)",[88],"2003-06","1994-02",711,[452],[1524,1495],"Parenteral Insulin",{"trials":1526,"activeCount":98},[],{"trials":1528,"activeCount":98},[],{"intervention":1530,"totalTrials":164,"cells":1531},"Tenofovir",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1548,"PHASE4":1560,"NA":1562},{"trials":1533,"activeCount":98},[],{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[1538],{"nctId":1539,"briefTitle":1540,"status":447,"phases":1541,"primaryCompletion":1542,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT00524173","Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B",[87],"2017-02-16","2007-08-29",35,[1428],[1547,1530],"Tenofovir & Emtricitabine",{"trials":1549,"activeCount":98},[1550],{"nctId":1551,"briefTitle":1552,"status":148,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT01369212","Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B",[88],"2021-03-08","2012-11",201,[1428],[1530,1559],"Peginterferon-alfa 2a and tenofovir",{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"intervention":1565,"totalTrials":94,"cells":1566},"SYNSORB Pk",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1585,"NA":1587},{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[1575],{"nctId":1576,"briefTitle":1577,"status":447,"phases":1578,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1584},"NCT00004465","Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome",[88],"2001-04-14","1997-07-27",145,[1583],"Hemolytic Uremic Syndrome",[1565],{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":98},[],{"intervention":1387,"totalTrials":94,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1603,"NA":1605},{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[1599],{"nctId":1377,"briefTitle":1378,"status":148,"phases":1600,"primaryCompletion":1380,"completion":1380,"start":1381,"enrollment":1382,"conditions":1601,"interventions":1602},[88],[1384],[1366,1386,1387],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"intervention":1608,"totalTrials":94,"cells":1609},"alendronate",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1630,"NA":1632},{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[1618],{"nctId":1619,"briefTitle":1620,"status":148,"phases":1621,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1629},"NCT00048841","Prevention of Osteoporosis in Men With Prostate Cancer",[88],"2005-12","2002-05",112,[1626,1627,1628],"Prostate Cancer","Osteoporosis","Hypogonadism",[1608],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"intervention":1635,"totalTrials":94,"cells":1636},"Sincalide",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1643,"PHASE4":1655,"NA":1657},{"trials":1638,"activeCount":98},[],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[1645],{"nctId":1646,"briefTitle":1647,"status":148,"phases":1648,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1653},"NCT00706381","Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)",[88],"2012-08-21","2008-06-23",31,[21],[1635,1654],"Ursodiol",{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"intervention":1654,"totalTrials":94,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1673,"NA":1675},{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[1669],{"nctId":1646,"briefTitle":1647,"status":148,"phases":1670,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":1671,"interventions":1672},[88],[21],[1635,1654],{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"intervention":1678,"totalTrials":94,"cells":1679},"Desipramine",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1686,"PHASE4":1701,"NA":1703},{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[1688],{"nctId":1689,"briefTitle":1690,"status":148,"phases":1691,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1700},"NCT00006157","Treatment of Functional Bowel Disorders",[88],"2001-03","1996-07",300,[1696,1697,1698,1699],"Irritable Bowel Syndrome","Constipation","Abdominal Pain","Functional Colonic Diseases",[1678],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"intervention":1103,"totalTrials":94,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1719,"NA":1721},{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[1715],{"nctId":1091,"briefTitle":1092,"status":148,"phases":1716,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1717,"interventions":1718},[88],[1099,541,1100,1101],[1103,1017],{"trials":1720,"activeCount":98},[],{"trials":1722,"activeCount":98},[],{"intervention":1724,"totalTrials":94,"cells":1725},"DR cysteamine bitartrate",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1745,"NA":1747},{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[1734],{"nctId":1735,"briefTitle":1736,"status":148,"phases":1737,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1744},"NCT01529268","Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children",[87,88],"2015-03","2015-09","2012-06",169,[1743],"Nonalcoholic Fatty Liver Disease (NAFLD)",[1724],{"trials":1746,"activeCount":98},[],{"trials":1748,"activeCount":98},[],{"intervention":1750,"totalTrials":94,"cells":1751},"Empagliflozin",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1770,"NA":1772},{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[1760],{"nctId":1761,"briefTitle":1762,"status":476,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1765,"enrollment":98,"conditions":1766,"interventions":1769},"NCT03173963","Empaglifozin in Early Diabetic Kidney Disease",[88],"2020-02-21","2017-05-27",[1767,1768],"Diabetic Kidney Disease","Diabetes Mellitus Type 2",[1750],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"intervention":1775,"totalTrials":94,"cells":1776},"Leptin",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1795,"NA":1797},{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[1785],{"nctId":1786,"briefTitle":1787,"status":1788,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":161,"conditions":1792,"interventions":1793},"NCT00073242","Low-Dose Leptin and the Formerly-Obese","UNKNOWN",[88],"2015-07","2000-07",[15],[1775,1794],"T3 repletion",{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"intervention":1794,"totalTrials":94,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[1809],{"nctId":1786,"briefTitle":1787,"status":1788,"phases":1810,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":161,"conditions":1811,"interventions":1812},[88],[15],[1775,1794],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"intervention":1818,"totalTrials":94,"cells":1819},"Etanercept",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1826,"PHASE4":1838,"NA":1840},{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[1828],{"nctId":1829,"briefTitle":1830,"status":148,"phases":1831,"primaryCompletion":1832,"completion":1832,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1837},"NCT00111956","Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome",[87,88],"2005-05","2004-04",56,[1836],"Metabolic Syndrome X",[1818],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[],{"intervention":1843,"totalTrials":94,"cells":1844},"Ursodeoxycholic Acid",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1863,"NA":1865},{"trials":1846,"activeCount":98},[],{"trials":1848,"activeCount":98},[],{"trials":1850,"activeCount":98},[],{"trials":1852,"activeCount":98},[1853],{"nctId":1854,"briefTitle":1855,"status":447,"phases":1856,"primaryCompletion":1857,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1862},"NCT00059202","Trial of High-dose Urso in Primary Sclerosing Cholangitis",[87,88],"2008-06","2002-07",150,[1861],"Primary Sclerosing Cholangitis",[1843],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[],{"intervention":1868,"totalTrials":94,"cells":1869},"Alfuzosin",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1887,"NA":1889},{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":98},[1878],{"nctId":1879,"briefTitle":1880,"status":148,"phases":1881,"primaryCompletion":479,"completion":479,"start":1882,"enrollment":1883,"conditions":1884,"interventions":1886},"NCT00103402","Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome",[88],"2005-02",272,[1885],"Prostatitis",[1868],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"intervention":1892,"totalTrials":94,"cells":1893},"Pregabalin",{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1912,"NA":1914},{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"trials":1899,"activeCount":98},[],{"trials":1901,"activeCount":98},[1902],{"nctId":1903,"briefTitle":1904,"status":148,"phases":1905,"primaryCompletion":479,"completion":1906,"start":1907,"enrollment":1908,"conditions":1909,"interventions":1911},"NCT00371033","Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)",[88],"2008-04-30","2006-03",324,[1910],"Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)",[1892],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"intervention":1917,"totalTrials":94,"cells":1918},"High Dose Multivitamin",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1938,"NA":1940},{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[1927],{"nctId":1928,"briefTitle":1929,"status":148,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1623,"enrollment":1932,"conditions":1933,"interventions":1937},"NCT00064753","Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)",[87,88],"2011-10",4110,[1934,1935,1936],"Chronic Kidney Disease","Cardiovascular Disease","Death",[1917],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"intervention":1943,"totalTrials":94,"cells":1944},"phylloquinone",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1962,"NA":1964},{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[1953],{"nctId":1954,"briefTitle":1955,"status":148,"phases":1956,"completion":1189,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1960},"NCT00062595","Vitamin K and Bone Turnover in Postmenopausal Women",[88],"2000-09",375,[1627],[1943,1961],"menatetranone",{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[],{"intervention":1961,"totalTrials":94,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[1976],{"nctId":1954,"briefTitle":1955,"status":148,"phases":1977,"completion":1189,"start":1957,"enrollment":1958,"conditions":1978,"interventions":1979},[88],[1627],[1943,1961],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"intervention":1985,"totalTrials":94,"cells":1986},"Clopidogrel",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":2006,"NA":2008},{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[1995],{"nctId":1996,"briefTitle":1997,"status":148,"phases":1998,"primaryCompletion":1999,"completion":1999,"start":2000,"enrollment":2001,"conditions":2002,"interventions":2005},"NCT03289520","Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis",[88],"2007-06-18","2003-01-07",877,[2003,2004],"Kidney Failure","Hemodialysis Fistula Thrombosis",[1985],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"intervention":2011,"totalTrials":94,"cells":2012},"Mycophenolate Mofetil",{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2034,"NA":2036},{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[2021],{"nctId":2022,"briefTitle":2023,"status":447,"phases":2024,"primaryCompletion":2025,"completion":2026,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2032},"NCT00451867","A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .",[88],"2008-02","2008-04","2007-03",210,[2030,2031],"Interstitial Cystitis","Painful Bladder Syndrome",[2011,2033],"Mycofenolate Mofetil",{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[],{"intervention":2033,"totalTrials":94,"cells":2039},{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2046,"PHASE4":2052,"NA":2054},{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[2048],{"nctId":2022,"briefTitle":2023,"status":447,"phases":2049,"primaryCompletion":2025,"completion":2026,"start":2027,"enrollment":2028,"conditions":2050,"interventions":2051},[88],[2030,2031],[2011,2033],{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":98},[],{"intervention":2057,"totalTrials":94,"cells":2058},"PTH1-84 in parent study",{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2078,"NA":2080},{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[2067],{"nctId":2068,"briefTitle":2069,"status":1788,"phases":2070,"primaryCompletion":2071,"completion":2072,"start":2073,"enrollment":2074,"conditions":2075,"interventions":2077},"NCT00856401","ADD-ON Study to Existing Hypoparathyroidism Studies",[88],"2020-12-31","2021-06-30","2010-09",62,[2076],"Hypoparathyroidism",[2057],{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[],{"intervention":2083,"totalTrials":94,"cells":2084},"Insulin Asparte",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2104,"NA":2106},{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[2093],{"nctId":2094,"briefTitle":2095,"status":148,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT00072904","Diabetes Therapy to Improve BMI and Lung Function in CF",[88],"2007-12","2001-06",108,[2101,24],"Cystic Fibrosis",[2083,2103],"Repaglinide",{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"intervention":2103,"totalTrials":94,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2122,"NA":2124},{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[2118],{"nctId":2094,"briefTitle":2095,"status":148,"phases":2119,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2120,"interventions":2121},[88],[2101,24],[2083,2103],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"intervention":2127,"totalTrials":94,"cells":2128},"Byetta",{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2135,"PHASE4":2146,"NA":2148},{"trials":2130,"activeCount":98},[],{"trials":2132,"activeCount":98},[],{"trials":2134,"activeCount":98},[],{"trials":2136,"activeCount":98},[2137],{"nctId":2138,"briefTitle":2139,"status":148,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":1859,"conditions":2143,"interventions":2145},"NCT00856609","The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects",[88],"2016-09-19","2009-03-03",[2144,15],"Weight Loss",[2127],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"intervention":2151,"totalTrials":94,"cells":2152},"Rosiglitazone",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2173,"NA":2175},{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[2161],{"nctId":2162,"briefTitle":2163,"status":148,"phases":2164,"primaryCompletion":2165,"completion":2166,"start":2167,"enrollment":2168,"conditions":2169,"interventions":2171},"NCT00081328","Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)",[88],"2011-02","2014-02","2004-05",699,[2170],"Diabetes Mellitus, Type II",[2172,2151],"Metformin",{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[],{"intervention":2178,"totalTrials":94,"cells":2179},"Medications needed to maintain usual blood pressure",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2200,"NA":2202},{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[2188],{"nctId":2189,"briefTitle":2190,"status":148,"phases":2191,"primaryCompletion":2192,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2198},"NCT04364113","The Modification of Diet in Renal Disease Study",[88],"1993-01-31","2000-12-31","1989-01-01",840,[2197],"Chronic Renal Disease",[2178,2199],"Medications needed to maintain low blood pressure",{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"intervention":2199,"totalTrials":94,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2212,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[],{"trials":2213,"activeCount":98},[2214],{"nctId":2189,"briefTitle":2190,"status":148,"phases":2215,"primaryCompletion":2192,"completion":2193,"start":2194,"enrollment":2195,"conditions":2216,"interventions":2217},[88],[2197],[2178,2199],{"trials":2219,"activeCount":98},[],{"trials":2221,"activeCount":98},[],{"intervention":2223,"totalTrials":94,"cells":2224},"Imipramine",{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2242,"NA":2244},{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[2233],{"nctId":2234,"briefTitle":2235,"status":148,"phases":2236,"completion":2237,"start":2238,"conditions":2239,"interventions":2241},"NCT00005575","Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy",[88],"2002-12","1999-01",[2240],"Chest Pain",[2223],{"trials":2243,"activeCount":98},[],{"trials":2245,"activeCount":98},[],{"intervention":2247,"totalTrials":94,"cells":2248},"Pegylated Interferon\u002Fribavirin",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2265,"NA":2267},{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[2257],{"nctId":2258,"briefTitle":2259,"status":148,"phases":2260,"primaryCompletion":994,"completion":2261,"start":291,"enrollment":2262,"conditions":2263,"interventions":2264},"NCT00100659","PEDS-C: Pegylated Interferon +\u002F- Ribavirin for Children With Hepatitis C",[88],"2010-02",114,[997],[2247],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"intervention":2270,"totalTrials":94,"cells":2271},"Methotrexate",{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2288,"NA":2290},{"trials":2273,"activeCount":98},[],{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[2280],{"nctId":2281,"briefTitle":2282,"status":148,"phases":2283,"completion":2284,"start":2285,"conditions":2286,"interventions":2287},"NCT00006168","Ursodiol-Methotrexate for Primary Biliary Cirrhosis",[88],"2004-03","1994-01",[1179],[2270],{"trials":2289,"activeCount":98},[],{"trials":2291,"activeCount":98},[],{"intervention":2293,"totalTrials":94,"cells":2294},"Aggrenox",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2312,"NA":2314},{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[2303],{"nctId":2304,"briefTitle":2305,"status":148,"phases":2306,"primaryCompletion":2307,"completion":2307,"start":2308,"enrollment":2309,"conditions":2310,"interventions":2311},"NCT00067119","Aggrenox Prevention of Access Stenosis",[88],"2008-01-31","2003-01-01",649,[2003],[2293],{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"intervention":2317,"totalTrials":94,"cells":2318},"Amitriptyline",{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2336,"NA":2338},{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[2327],{"nctId":2328,"briefTitle":2329,"status":148,"phases":2330,"primaryCompletion":2026,"completion":2331,"start":1882,"enrollment":2332,"conditions":2333,"interventions":2335},"NCT00124306","Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)",[88],"2008-12",271,[2334,2030],"Bladder Diseases",[2317],{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[],{"intervention":2341,"totalTrials":94,"cells":2342},"Ramipril",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2365,"NA":2367},{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[2351],{"nctId":2352,"briefTitle":2353,"status":148,"phases":2354,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":2358,"conditions":2359,"interventions":2362},"NCT04364139","African American Study of Kidney Disease and Hypertension",[88],"2001-09-30","2007-06-30","1995-02-01",1094,[2360,2361],"Hypertensive Nephrosclerosis","Chronic Renal Insufficiency",[2341,2363,2364],"Amlodipine","Metoprolol",{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"intervention":2363,"totalTrials":94,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2383,"NA":2385},{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[2379],{"nctId":2352,"briefTitle":2353,"status":148,"phases":2380,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":2358,"conditions":2381,"interventions":2382},[88],[2360,2361],[2341,2363,2364],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"intervention":2364,"totalTrials":94,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2395,"PHASE4":2401,"NA":2403},{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[2397],{"nctId":2352,"briefTitle":2353,"status":148,"phases":2398,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":2358,"conditions":2399,"interventions":2400},[88],[2360,2361],[2341,2363,2364],{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"intervention":2406,"totalTrials":94,"cells":2407},"Gabapentin",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2427,"NA":2429},{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[],{"trials":2415,"activeCount":98},[2416],{"nctId":2417,"briefTitle":2418,"status":148,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":1152,"enrollment":2421,"conditions":2422,"interventions":2426},"NCT00058890","Gabapentin to Treat Itch in Patients With Liver Disease",[88],"2004-01",15,[2423,2424,540,1178,2425],"Liver Disease","Cholestasis","Itching",[2406],{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"intervention":2432,"totalTrials":94,"cells":2433},"Nortriptyline Hydrochloride",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2452,"NA":2454},{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[2442],{"nctId":2443,"briefTitle":2444,"status":148,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2451},"NCT00765895","Nortriptyline for Idiopathic Gastroparesis",[88],"2012-10","2009-01",130,[2450],"Idiopathic Gastroparesis",[2432],{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[],{"intervention":2457,"totalTrials":94,"cells":2458},"Trimethoprim-Sulfamethoxazole",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2477,"NA":2479},{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[2467],{"nctId":2468,"briefTitle":2469,"status":148,"phases":2470,"primaryCompletion":993,"completion":2471,"start":1014,"enrollment":2472,"conditions":2473,"interventions":2476},"NCT00405704","Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)",[88],"2014-05",607,[2474,2475],"Vesicoureteral Reflux","Urinary Tract Infections",[2457],{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[],{"intervention":2482,"totalTrials":94,"cells":2483},"Cyclosporin",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2502,"NA":2504},{"trials":2485,"activeCount":98},[],{"trials":2487,"activeCount":98},[],{"trials":2489,"activeCount":98},[],{"trials":2491,"activeCount":98},[2492],{"nctId":2493,"briefTitle":2494,"status":148,"phases":2495,"primaryCompletion":1095,"completion":1095,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2500},"NCT00135811","Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)",[88],"2004-11",207,[2499],"Glomerulosclerosis, Focal",[2482,2501],"MMF and Dexamethasone",{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[],{"intervention":2501,"totalTrials":94,"cells":2507},{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2520,"NA":2522},{"trials":2509,"activeCount":98},[],{"trials":2511,"activeCount":98},[],{"trials":2513,"activeCount":98},[],{"trials":2515,"activeCount":98},[2516],{"nctId":2493,"briefTitle":2494,"status":148,"phases":2517,"primaryCompletion":1095,"completion":1095,"start":2496,"enrollment":2497,"conditions":2518,"interventions":2519},[88],[2499],[2482,2501],{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[],{"intervention":2525,"totalTrials":94,"cells":2526},"Timolol Maleate",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2545,"NA":2547},{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[2535],{"nctId":2536,"briefTitle":2537,"status":148,"phases":2538,"primaryCompletion":1025,"completion":1025,"start":1381,"enrollment":2539,"conditions":2540,"interventions":2544},"NCT00006398","Prevention of Esophageal Varices by Beta-Adrenergic Blockers",[88],213,[2541,2542,2543],"Esophageal and Gastric Varices","Liver Cirrhosis","Portal Hypertension",[2525],{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[],{"intervention":2550,"totalTrials":94,"cells":2551},"Losartan",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2569,"NA":2571},{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[2560],{"nctId":2561,"briefTitle":2562,"status":148,"phases":2563,"primaryCompletion":1435,"completion":2564,"start":2565,"enrollment":2566,"conditions":2567,"interventions":2568},"NCT00340678","Renoprotection in Early Diabetic Nephropathy in Pima Indians",[88],"2014-03","1995-08",170,[1384],[2550],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"intervention":2574,"totalTrials":94,"cells":2575},"Saw Palmetto",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2593,"NA":2595},{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[],{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[2584],{"nctId":2585,"briefTitle":2586,"status":148,"phases":2587,"completion":2237,"start":2588,"enrollment":2589,"conditions":2590,"interventions":2592},"NCT00037154","Saw Palmetto Extract in Benign Prostatic Hyperplasia",[88],"1999-08",224,[2591],"Benign Prostatic Hyperplasia",[2574],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"intervention":2598,"totalTrials":94,"cells":2599},"Oral dexamethasone",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2606,"PHASE4":2618,"NA":2620},{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":98},[2608],{"nctId":2609,"briefTitle":2610,"status":148,"phases":2611,"primaryCompletion":411,"completion":411,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2617},"NCT00065611","Steroid Treatment for Kidney Disease",[88],"2003-07",8,[2615,2616],"Nephrosis","Focal Lipoid Glomerulosclerosis",[2598],{"trials":2619,"activeCount":98},[],{"trials":2621,"activeCount":98},[],{"intervention":2623,"totalTrials":94,"cells":2624},"Finasteride and Alfuzosin",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2641,"NA":2643},{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[],{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[2633],{"nctId":2634,"briefTitle":2635,"status":447,"phases":2636,"completion":2637,"start":1833,"enrollment":2638,"conditions":2639,"interventions":2640},"NCT00064649","Minimally Invasive Surgical Therapy for BPH",[88],"2006-06",49,[2591],[2623],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"intervention":1524,"totalTrials":94,"cells":2646},{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2659,"NA":2661},{"trials":2648,"activeCount":98},[],{"trials":2650,"activeCount":98},[],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[2655],{"nctId":1516,"briefTitle":1517,"status":148,"phases":2656,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":2657,"interventions":2658},[88],[452],[1524,1495],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"intervention":2664,"totalTrials":94,"cells":2665},"Granulocyte colony-stimulating factor",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2682,"NA":2684},{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[2674],{"nctId":2675,"briefTitle":2676,"status":148,"phases":2677,"completion":1858,"start":2678,"enrollment":35,"conditions":2679,"interventions":2681},"NCT00005782","Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait",[88],"2000-01",[2680],"Sickle Cell Trait",[2664],{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[],{"intervention":2687,"totalTrials":94,"cells":2688},"ADD On Dosing",{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2693,"PHASE3":2695,"PHASE4":2706,"NA":2708},{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[2697],{"nctId":2698,"briefTitle":2699,"status":148,"phases":2700,"primaryCompletion":2331,"completion":2331,"start":2701,"enrollment":2702,"conditions":2703,"interventions":2705},"NCT00582777","African American Study of Kidney Disease and Hypertension ABPM Pilot Study",[87,88],"2007-11",180,[2704],"Hypertensive Renal Disease",[2687],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"intervention":2711,"totalTrials":94,"cells":2712},"N-acetylcysteine",{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2730,"NA":2732},{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[2721],{"nctId":2722,"briefTitle":2723,"status":148,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":2727,"conditions":2728,"interventions":2729},"NCT00004467","Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen",[88],"2006-11","1998-06",173,[701],[2711],{"trials":2731,"activeCount":98},[],{"trials":2733,"activeCount":98},[],{"intervention":2735,"totalTrials":94,"cells":2736},"Doxazosin",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2743,"PHASE4":2759,"NA":2761},{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[],{"trials":2742,"activeCount":98},[],{"trials":2744,"activeCount":98},[2745],{"nctId":2746,"briefTitle":2747,"status":148,"phases":2748,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":2751,"conditions":2752,"interventions":2755},"NCT00021814","Medical Therapy of Prostatic Symptoms",[88],"2001-11-30","1995-12",3407,[2753,2754],"Prostatic Hyperplasia","Prostatic Hypertrophy, Benign",[2735,2756,2757,2758],"Finasteride","Doxazosin placebo","Finasteride placebo",{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[],{"intervention":2756,"totalTrials":94,"cells":2764},{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2777,"NA":2779},{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[2773],{"nctId":2746,"briefTitle":2747,"status":148,"phases":2774,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":2751,"conditions":2775,"interventions":2776},[88],[2753,2754],[2735,2756,2757,2758],{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[],{"intervention":2757,"totalTrials":94,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2789,"PHASE4":2795,"NA":2797},{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[2791],{"nctId":2746,"briefTitle":2747,"status":148,"phases":2792,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":2751,"conditions":2793,"interventions":2794},[88],[2753,2754],[2735,2756,2757,2758],{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"intervention":2758,"totalTrials":94,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2813,"NA":2815},{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[2809],{"nctId":2746,"briefTitle":2747,"status":148,"phases":2810,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":2751,"conditions":2811,"interventions":2812},[88],[2753,2754],[2735,2756,2757,2758],{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[],{"intervention":1559,"totalTrials":94,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2831,"NA":2833},{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[2827],{"nctId":1551,"briefTitle":1552,"status":148,"phases":2828,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":2829,"interventions":2830},[88],[1428],[1530,1559],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"intervention":2836,"totalTrials":2837,"cells":2838},"Sirolimus",4,{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[2845,2854,2863,2872],{"nctId":2846,"briefTitle":2847,"status":148,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":35,"conditions":2851,"interventions":2853},"NCT00050713","Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy",[87],"2007-08-27","2002-12-17",[490,2852],"Lupus Membranous Nepropathy",[2836],{"nctId":2855,"briefTitle":2856,"status":148,"phases":2857,"completion":2858,"start":2859,"enrollment":256,"conditions":2860,"interventions":2862},"NCT00040508","Sirolimus for Focal Segmental Glomerulosclerosis",[87],"2005-01","2002-06",[2861],"Focal Glomerulosclerosis",[2836],{"nctId":2864,"briefTitle":2865,"status":148,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":2420,"enrollment":1651,"conditions":2868,"interventions":2870},"NCT00076570","Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation",[87],"2012-08",[2869],"Kidney Transplantation",[2836,2871],"Tacrolimus",{"nctId":2873,"briefTitle":2874,"status":148,"phases":2875,"primaryCompletion":2097,"completion":2097,"start":1336,"enrollment":35,"conditions":2876,"interventions":2877},"NCT00006178","Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection",[87],[2003],[2836,2878],"Thymoglobulin",{"trials":2880,"activeCount":98},[],{"trials":2882,"activeCount":98},[],{"trials":2884,"activeCount":98},[],{"intervention":2886,"totalTrials":279,"cells":2887},"Allopurinol",{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2923,"PHASE4":2925,"NA":2927},{"trials":2889,"activeCount":98},[],{"trials":2891,"activeCount":98},[],{"trials":2893,"activeCount":98},[2894,2905,2914],{"nctId":2895,"briefTitle":2896,"status":148,"phases":2897,"primaryCompletion":2898,"completion":2898,"start":2899,"enrollment":230,"conditions":2900,"interventions":2903},"NCT00288158","Primary Prevention of Hypertension in Obese Adolescents",[87],"2011-01","2008-09",[15,2901,2902],"Pre-Hypertension","Hyperuricemia",[2886,2904],"Probenecid",{"nctId":2906,"briefTitle":2907,"status":148,"phases":2908,"primaryCompletion":2027,"completion":2909,"start":2910,"enrollment":256,"conditions":2911,"interventions":2913},"NCT00288184","Uric Acid in Essential Hypertension in Children",[87],"2007-08","2004-09",[2912],"Essential Hypertension",[2886],{"nctId":2915,"briefTitle":2916,"status":476,"phases":2917,"primaryCompletion":479,"completion":1857,"start":2918,"enrollment":98,"conditions":2919,"interventions":2922},"NCT00288171","Allopurinol for Renal Transplant Associated Hypertension in Children",[86,87],"2006-02",[2920,2921],"Hypertension","Renal Transplant",[2886],{"trials":2924,"activeCount":98},[],{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"intervention":2930,"totalTrials":279,"cells":2931},"Lonafarnib",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2933,"activeCount":98},[],{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[2938,2947,2958],{"nctId":2939,"briefTitle":2940,"status":148,"phases":2941,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":1081,"conditions":2944,"interventions":2946},"NCT01495585","Lonafarnib for Chronic Hepatitis D",[87],"2015-04","2011-12",[2945],"Hepatitis D",[2930],{"nctId":2948,"briefTitle":2949,"status":148,"phases":2950,"primaryCompletion":2951,"completion":2952,"start":2953,"enrollment":19,"conditions":2954,"interventions":2955},"NCT03600714","Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon",[87],"2020-02-05","2020-08-11","2018-08-01",[2423,2945],[2956,2930,2957],"Peg-interferon lambda","Ritonavir",{"nctId":2959,"briefTitle":2960,"status":148,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":2963,"enrollment":2964,"conditions":2965,"interventions":2966},"NCT02511431","Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir",[87],"2017-02-23","2015-07-29",22,[2945],[2930,2957],{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"intervention":2974,"totalTrials":164,"cells":2975},"Cyclophosphamide",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[2982,2990],{"nctId":2983,"briefTitle":2984,"status":148,"phases":2985,"primaryCompletion":1392,"completion":1392,"start":2986,"enrollment":2421,"conditions":2987,"interventions":2989},"NCT00007475","Permeability Factor in Focal Segmental Glomerulosclerosis",[86,87],"2000-12",[2988],"Focal Segmental Glomerulosclerosis",[2974],{"nctId":2991,"briefTitle":2992,"status":148,"phases":2993,"completion":2910,"start":2994,"enrollment":2995,"conditions":2996,"interventions":2998},"NCT00001212","Drug Therapy in Lupus Nephropathy",[87],"1986-11",45,[295,2997],"Systemic Lupus Erythematosus",[2999,3000,3001],"prednisone","cyclophosphamide","cyclosporin A",{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":98},[],{"intervention":2999,"totalTrials":164,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3011,"activeCount":98},[],{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[3016,3026],{"nctId":3017,"briefTitle":3018,"status":148,"phases":3019,"primaryCompletion":2909,"completion":2909,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3024},"NCT00004448","Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy",[87],"1997-11",96,[3023],"IgA Glomerulonephritis",[3025,2999],"omega-3 fatty acids",{"nctId":2991,"briefTitle":2992,"status":148,"phases":3027,"completion":2910,"start":2994,"enrollment":2995,"conditions":3028,"interventions":3029},[87],[295,2997],[2999,3000,3001],{"trials":3031,"activeCount":98},[],{"trials":3033,"activeCount":98},[],{"trials":3035,"activeCount":98},[],{"intervention":3037,"totalTrials":164,"cells":3038},"Sitagliptin",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3052,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[3043],{"nctId":3044,"briefTitle":3045,"status":148,"phases":3046,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":412,"conditions":3049,"interventions":3051},"NCT00813228","Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals",[86],"2019-11-26","2009-01-06",[3050,1768],"Diabetes Mellitus Type 1",[3037],{"trials":3053,"activeCount":98},[3054],{"nctId":3055,"briefTitle":3056,"status":447,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":981,"conditions":3060,"interventions":3062},"NCT00837759","Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes",[87],"2011-03","2009-02",[3050,3061],"Autoimmune Diabetes",[3063,3064,3037,3065,3066],"Insulin","Lansoprazole","Diamyd","GAD65",{"trials":3068,"activeCount":98},[],{"trials":3070,"activeCount":98},[],{"trials":3072,"activeCount":98},[],{"intervention":2957,"totalTrials":164,"cells":3074},{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3076,"activeCount":98},[],{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":98},[3081,3085],{"nctId":2948,"briefTitle":2949,"status":148,"phases":3082,"primaryCompletion":2951,"completion":2952,"start":2953,"enrollment":19,"conditions":3083,"interventions":3084},[87],[2423,2945],[2956,2930,2957],{"nctId":2959,"briefTitle":2960,"status":148,"phases":3086,"primaryCompletion":2962,"completion":2962,"start":2963,"enrollment":2964,"conditions":3087,"interventions":3088},[87],[2945],[2930,2957],{"trials":3090,"activeCount":98},[],{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"intervention":3096,"totalTrials":94,"cells":3097},"CTLA-4 Ig",{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3099,"activeCount":98},[],{"trials":3101,"activeCount":98},[],{"trials":3103,"activeCount":98},[3104],{"nctId":3105,"briefTitle":3106,"status":148,"phases":3107,"primaryCompletion":1435,"completion":1435,"start":2025,"enrollment":1624,"conditions":3108,"interventions":3109},"NCT00505375","Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus",[87],[427],[3096],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[],{"trials":3115,"activeCount":98},[],{"intervention":2904,"totalTrials":94,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[3124],{"nctId":2895,"briefTitle":2896,"status":148,"phases":3125,"primaryCompletion":2898,"completion":2898,"start":2899,"enrollment":230,"conditions":3126,"interventions":3127},[87],[15,2901,2902],[2886,2904],{"trials":3129,"activeCount":98},[],{"trials":3131,"activeCount":98},[],{"trials":3133,"activeCount":98},[],{"intervention":3135,"totalTrials":94,"cells":3136},"Drug: f-18 fallypride",{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3138,"activeCount":98},[],{"trials":3140,"activeCount":98},[],{"trials":3142,"activeCount":98},[3143],{"nctId":3144,"briefTitle":3145,"status":148,"phases":3146,"primaryCompletion":3147,"completion":3148,"start":3149,"enrollment":3150,"conditions":3151,"interventions":3152},"NCT00846040","Reduced Carbohydrate Versus Fat in Obese Subjects",[87],"2014-02-24","2014-10-20","2009-02-13",43,[15],[3135],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[],{"intervention":3160,"totalTrials":94,"cells":3161},"LADR Treatment",{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[],{"trials":3167,"activeCount":98},[3168],{"nctId":3169,"briefTitle":3170,"status":148,"phases":3171,"primaryCompletion":478,"completion":478,"start":1137,"enrollment":3172,"conditions":3173,"interventions":3174},"NCT00135798","Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation",[87],79,[1040],[3160],{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"intervention":3182,"totalTrials":94,"cells":3183},"CTLA4-Ig",{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3188,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3185,"activeCount":98},[],{"trials":3187,"activeCount":98},[],{"trials":3189,"activeCount":98},[3190],{"nctId":3191,"briefTitle":3192,"status":148,"phases":3193,"primaryCompletion":3194,"completion":3195,"start":3196,"enrollment":3197,"conditions":3198,"interventions":3201},"NCT01773707","CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1",[87],"2021-12-14","2022-12-14","2013-03",212,[3199,3200],"Abnormal Glucose Tolerance","Type 1 Diabetes",[3182],{"trials":3203,"activeCount":98},[],{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[],{"intervention":999,"totalTrials":94,"cells":3209},{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3214,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3211,"activeCount":98},[],{"trials":3213,"activeCount":98},[],{"trials":3215,"activeCount":98},[3216],{"nctId":990,"briefTitle":991,"status":148,"phases":3217,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":3218,"interventions":3219},[87],[997],[999,980],{"trials":3221,"activeCount":98},[],{"trials":3223,"activeCount":98},[],{"trials":3225,"activeCount":98},[],{"intervention":3227,"totalTrials":94,"cells":3228},"hu Leptin",{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3230,"activeCount":98},[],{"trials":3232,"activeCount":98},[],{"trials":3234,"activeCount":98},[3235],{"nctId":3236,"briefTitle":147,"status":148,"phases":3237,"completion":1175,"start":1096,"enrollment":270,"conditions":3238,"interventions":3239},"NCT00005905",[87],[34],[3227],{"trials":3241,"activeCount":98},[],{"trials":3243,"activeCount":98},[],{"trials":3245,"activeCount":98},[],{"intervention":3247,"totalTrials":94,"cells":3248},"Liothyronine and Levothyroxine",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":98},[3255],{"nctId":3256,"briefTitle":3257,"status":148,"phases":3258,"primaryCompletion":3259,"completion":3259,"start":1174,"enrollment":25,"conditions":3260,"interventions":3262},"NCT00106119","Thyroid and Glucose and Energy Metabolism",[87],"2013-11",[3261],"Thyroid Diseases",[3247],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[],{"trials":3268,"activeCount":98},[],{"intervention":3270,"totalTrials":94,"cells":3271},"Lithium Carbonate",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":98},[3278],{"nctId":3279,"briefTitle":3280,"status":148,"phases":3281,"primaryCompletion":2943,"completion":2943,"start":1036,"enrollment":3282,"conditions":3283,"interventions":3285},"NCT00251316","Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer",[87],34,[258,3284],"Differentiated Thyroid Carcinoma",[3270],{"trials":3287,"activeCount":98},[],{"trials":3289,"activeCount":98},[],{"trials":3291,"activeCount":98},[],{"intervention":3293,"totalTrials":94,"cells":3294},"Islet Transplantation",{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3310,"PHASE4":3312,"NA":3314},{"trials":3296,"activeCount":98},[],{"trials":3298,"activeCount":98},[],{"trials":3300,"activeCount":98},[3301],{"nctId":3302,"briefTitle":3303,"status":148,"phases":3304,"primaryCompletion":3305,"completion":3306,"start":3307,"enrollment":1067,"conditions":3308,"interventions":3309},"NCT00006505","Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression",[87],"2002-06-30","2020-04-21","2000-11-16",[3050],[3293],{"trials":3311,"activeCount":98},[],{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[],{"intervention":3317,"totalTrials":94,"cells":3318},"canakinumab",{"EARLY_PHASE1":3319,"PHASE1":3321,"PHASE2":3323,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3320,"activeCount":98},[],{"trials":3322,"activeCount":98},[],{"trials":3324,"activeCount":98},[3325],{"nctId":3326,"briefTitle":3327,"status":148,"phases":3328,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":3332,"interventions":3336},"NCT00947427","Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes",[87],"2013-04","2010-10",71,[3200,3333,3334,3335],"Preservation of Insulin Secretion","Newly Diagnosed Type 1 Diabetes","Canakinumab in Type 1 Diabetes",[3317],{"trials":3338,"activeCount":98},[],{"trials":3340,"activeCount":98},[],{"trials":3342,"activeCount":98},[],{"intervention":3344,"totalTrials":94,"cells":3345},"Olanzapine",{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[3352],{"nctId":3353,"briefTitle":3354,"status":148,"phases":3355,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":256,"conditions":3358,"interventions":3360},"NCT00446992","Diabetes in Neuropsychiatric Disorders",[86,87],"2010-03","2006-04",[3359],"Schizophrenia",[3344],{"trials":3362,"activeCount":98},[],{"trials":3364,"activeCount":98},[],{"trials":3366,"activeCount":98},[],{"intervention":3368,"totalTrials":94,"cells":3369},"capsaicin",{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3374,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3371,"activeCount":98},[],{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[3376],{"nctId":3377,"briefTitle":3378,"status":148,"phases":3379,"primaryCompletion":2909,"completion":2909,"start":3380,"enrollment":3381,"conditions":3382,"interventions":3384},"NCT00004316","Phase I\u002FII Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis",[86,87],"1995-06",139,[2030,3383],"Vulvar Diseases",[3368],{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[],{"trials":3390,"activeCount":98},[],{"intervention":3392,"totalTrials":94,"cells":3393},"Parathyroid hormone",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3407,"PHASE4":3409,"NA":3411},{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[3400],{"nctId":3401,"briefTitle":3402,"status":148,"phases":3403,"completion":3404,"start":2588,"conditions":3405,"interventions":3406},"NCT00004993","Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis",[87],"2001-08",[1627],[3392],{"trials":3408,"activeCount":98},[],{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[],{"intervention":3414,"totalTrials":94,"cells":3415},"Sandostatin LAR Depot versus transsphenoidal surgery",{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[3422],{"nctId":3423,"briefTitle":3424,"status":148,"phases":3425,"completion":1858,"start":2588,"enrollment":122,"conditions":3426,"interventions":3429},"NCT00001860","Sandostatin LAR Depot vs. Surgery for Treating Acromegaly",[87],[3427,3428],"Acromegaly","Pituitary Neoplasm",[3414],{"trials":3431,"activeCount":98},[],{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"intervention":3437,"totalTrials":94,"cells":3438},"Liothyronine",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3440,"activeCount":98},[],{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[3445],{"nctId":3446,"briefTitle":3447,"status":148,"phases":3448,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":981,"conditions":3451,"interventions":3453},"NCT02457897","Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations",[87],"2018-09-18","2015-04-17",[232,24,3452],"Abnormal Glucose Metabolism",[3437],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"trials":3459,"activeCount":98},[],{"intervention":3461,"totalTrials":94,"cells":3462},"fenofibrate",{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3467,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3464,"activeCount":98},[],{"trials":3466,"activeCount":98},[],{"trials":3468,"activeCount":98},[3469],{"nctId":3470,"briefTitle":3471,"status":148,"phases":3472,"completion":1832,"start":3473,"enrollment":1176,"conditions":3474,"interventions":3476},"NCT00361751","Substrate Cycling in Energy Metabolism",[87],"2003-05",[3475,232],"Burns",[3461],{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[],{"trials":3482,"activeCount":98},[],{"intervention":1008,"totalTrials":94,"cells":3484},{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3486,"activeCount":98},[],{"trials":3488,"activeCount":98},[],{"trials":3490,"activeCount":98},[3491],{"nctId":1001,"briefTitle":1002,"status":148,"phases":3492,"primaryCompletion":1004,"completion":1005,"start":1004,"enrollment":170,"conditions":3493,"interventions":3494},[86,87],[997],[1008,980],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"intervention":3502,"totalTrials":94,"cells":3503},"Atorvastatin",{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"trials":3509,"activeCount":98},[3510],{"nctId":3511,"briefTitle":3512,"status":447,"phases":3513,"primaryCompletion":3514,"completion":3514,"start":3515,"enrollment":122,"conditions":3516,"interventions":3517},"NCT00004466","Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome",[87],"1999-12","1998-10",[295,135],[3502],{"trials":3519,"activeCount":98},[],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[],{"intervention":3525,"totalTrials":94,"cells":3526},"botulinum toxin type A",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3542,"PHASE4":3544,"NA":3546},{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"trials":3532,"activeCount":98},[3533],{"nctId":3534,"briefTitle":3535,"status":148,"phases":3536,"primaryCompletion":3537,"completion":478,"start":3538,"enrollment":3539,"conditions":3540,"interventions":3541},"NCT00451191","Botulinum Toxin Injection for the Management of BPH",[87],"2009-06","2006-10",134,[2591],[3525],{"trials":3543,"activeCount":98},[],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[],{"intervention":3549,"totalTrials":94,"cells":3550},"Interferon",{"EARLY_PHASE1":3551,"PHASE1":3553,"PHASE2":3555,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3552,"activeCount":98},[],{"trials":3554,"activeCount":98},[],{"trials":3556,"activeCount":98},[3557],{"nctId":3558,"briefTitle":3559,"status":148,"phases":3560,"completion":3561,"start":3562,"enrollment":571,"conditions":3563,"interventions":3566},"NCT00001228","Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer",[87],"2007-09-06","1988-10-25",[3564,3565],"Islet Cell Adenoma","Zollinger Ellison Syndrome",[3549],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"trials":3572,"activeCount":98},[],{"intervention":3574,"totalTrials":94,"cells":3575},"Losartan potassium",{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[3582],{"nctId":3583,"briefTitle":3584,"status":447,"phases":3585,"primaryCompletion":3586,"completion":3586,"start":3587,"enrollment":3588,"conditions":3589,"interventions":3591},"NCT03467217","Losartan for the Treatment of Pediatric NAFLD",[87],"2020-06-30","2018-10-02",83,[3590],"NAFLD - Nonalcoholic Fatty Liver Disease",[3574],{"trials":3593,"activeCount":98},[],{"trials":3595,"activeCount":98},[],{"trials":3597,"activeCount":98},[],{"intervention":3599,"totalTrials":94,"cells":3600},"ulipristal acetate 20 mg",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3616,"PHASE4":3618,"NA":3620},{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[],{"trials":3606,"activeCount":98},[3607],{"nctId":3608,"briefTitle":3609,"status":148,"phases":3610,"primaryCompletion":3611,"completion":411,"start":2918,"enrollment":9,"conditions":3612,"interventions":3614},"NCT00290251","Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914",[87],"2009-07",[3613],"Leiomyoma",[3599,3615],"ulipristal acetate 10 mg",{"trials":3617,"activeCount":98},[],{"trials":3619,"activeCount":98},[],{"trials":3621,"activeCount":98},[],{"intervention":3615,"totalTrials":94,"cells":3623},{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3634,"PHASE4":3636,"NA":3638},{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[3630],{"nctId":3608,"briefTitle":3609,"status":148,"phases":3631,"primaryCompletion":3611,"completion":411,"start":2918,"enrollment":9,"conditions":3632,"interventions":3633},[87],[3613],[3599,3615],{"trials":3635,"activeCount":98},[],{"trials":3637,"activeCount":98},[],{"trials":3639,"activeCount":98},[],{"intervention":3641,"totalTrials":94,"cells":3642},"Peginterferon Alpha-2a",{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[],{"trials":3648,"activeCount":98},[3649],{"nctId":3650,"briefTitle":3651,"status":148,"phases":3652,"primaryCompletion":1435,"completion":2446,"start":3404,"enrollment":30,"conditions":3653,"interventions":3654},"NCT00023322","Pegylated Interferon to Treat Chronic Hepatitis D",[87],[2945],[3641],{"trials":3656,"activeCount":98},[],{"trials":3658,"activeCount":98},[],{"trials":3660,"activeCount":98},[],{"intervention":3662,"totalTrials":94,"cells":3663},"combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin",{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[3670],{"nctId":3671,"briefTitle":3672,"status":148,"phases":3673,"completion":3674,"start":3675,"enrollment":3676,"conditions":3677,"interventions":3679},"NCT00001165","Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas",[87],"2003-08","1978-09",999,[3564,3678,3565],"Neoplasm Metastasis",[3662],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[],{"intervention":3687,"totalTrials":94,"cells":3688},"Lamivudine and adefovir",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3690,"activeCount":98},[],{"trials":3692,"activeCount":98},[],{"trials":3694,"activeCount":98},[3695],{"nctId":3696,"briefTitle":3697,"status":148,"phases":3698,"primaryCompletion":3699,"completion":3700,"start":3404,"enrollment":3701,"conditions":3702,"interventions":3705},"NCT00023309","Lamivudine and Adefovir to Treat Chronic Hepatitis B",[87],"2010-04","2013-08",41,[3703,1428,3704],"HBV (Hepatitis B Virus)","Hepatitis",[3687,3706],"Adefovir alone",{"trials":3708,"activeCount":98},[],{"trials":3710,"activeCount":98},[],{"trials":3712,"activeCount":98},[],{"intervention":3706,"totalTrials":94,"cells":3714},{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3716,"activeCount":98},[],{"trials":3718,"activeCount":98},[],{"trials":3720,"activeCount":98},[3721],{"nctId":3696,"briefTitle":3697,"status":148,"phases":3722,"primaryCompletion":3699,"completion":3700,"start":3404,"enrollment":3701,"conditions":3723,"interventions":3724},[87],[3703,1428,3704],[3687,3706],{"trials":3726,"activeCount":98},[],{"trials":3728,"activeCount":98},[],{"trials":3730,"activeCount":98},[],{"intervention":3732,"totalTrials":94,"cells":3733},"hepatitis B immune globulin",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3749,"PHASE4":3751,"NA":3753},{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[3740],{"nctId":3741,"briefTitle":3742,"status":476,"phases":3743,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":98,"conditions":3746,"interventions":3747},"NCT03575208","Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B",[87],"2022-03-29","2019-02-13",[573],[3732,3748],"Pegylated interferon alfa",{"trials":3750,"activeCount":98},[],{"trials":3752,"activeCount":98},[],{"trials":3754,"activeCount":98},[],{"intervention":3748,"totalTrials":94,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"trials":3762,"activeCount":98},[3763],{"nctId":3741,"briefTitle":3742,"status":476,"phases":3764,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":98,"conditions":3765,"interventions":3766},[87],[573],[3732,3748],{"trials":3768,"activeCount":98},[],{"trials":3770,"activeCount":98},[],{"trials":3772,"activeCount":98},[],{"intervention":3774,"totalTrials":94,"cells":3775},"Vitamin E",{"EARLY_PHASE1":3776,"PHASE1":3778,"PHASE2":3780,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3777,"activeCount":98},[],{"trials":3779,"activeCount":98},[],{"trials":3781,"activeCount":98},[3782],{"nctId":3783,"briefTitle":3784,"status":148,"phases":3785,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":3789,"conditions":3790,"interventions":3793},"NCT04801849","Vitamin E Dosing Study",[87],"2025-03-04","2025-06-30","2022-08-05",200,[3791,3792],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[3774],{"trials":3795,"activeCount":98},[],{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[],{"intervention":3025,"totalTrials":94,"cells":3801},{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3803,"activeCount":98},[],{"trials":3805,"activeCount":98},[],{"trials":3807,"activeCount":98},[3808],{"nctId":3017,"briefTitle":3018,"status":148,"phases":3809,"primaryCompletion":2909,"completion":2909,"start":3020,"enrollment":3021,"conditions":3810,"interventions":3811},[87],[3023],[3025,2999],{"trials":3813,"activeCount":98},[],{"trials":3815,"activeCount":98},[],{"trials":3817,"activeCount":98},[],{"intervention":3819,"totalTrials":94,"cells":3820},"GAD-Alum",{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3825,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[3827],{"nctId":3828,"briefTitle":3829,"status":148,"phases":3830,"primaryCompletion":1435,"completion":1435,"start":3059,"enrollment":1581,"conditions":3831,"interventions":3832},"NCT00529399","Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects",[87],[427],[3819,3833,3834],"GAD-Alum and Aluminum hydroxide","Aluminum hydroxide",{"trials":3836,"activeCount":98},[],{"trials":3838,"activeCount":98},[],{"trials":3840,"activeCount":98},[],{"intervention":3833,"totalTrials":94,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":98},[],{"trials":3846,"activeCount":98},[],{"trials":3848,"activeCount":98},[3849],{"nctId":3828,"briefTitle":3829,"status":148,"phases":3850,"primaryCompletion":1435,"completion":1435,"start":3059,"enrollment":1581,"conditions":3851,"interventions":3852},[87],[427],[3819,3833,3834],{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"trials":3858,"activeCount":98},[],{"intervention":3834,"totalTrials":94,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[3867],{"nctId":3828,"briefTitle":3829,"status":148,"phases":3868,"primaryCompletion":1435,"completion":1435,"start":3059,"enrollment":1581,"conditions":3869,"interventions":3870},[87],[427],[3819,3833,3834],{"trials":3872,"activeCount":98},[],{"trials":3874,"activeCount":98},[],{"trials":3876,"activeCount":98},[],{"intervention":3878,"totalTrials":94,"cells":3879},"Actos",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[3886],{"nctId":3887,"briefTitle":3888,"status":148,"phases":3889,"primaryCompletion":3059,"completion":3059,"start":1519,"enrollment":25,"conditions":3890,"interventions":3891},"NCT00062764","Treating Nonalcoholic Steatohepatitis With Pioglitazone",[87],[3704],[3878],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[],{"trials":3897,"activeCount":98},[],{"intervention":3899,"totalTrials":94,"cells":3900},"Liraglutide",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[3907],{"nctId":3908,"briefTitle":3909,"status":148,"phases":3910,"primaryCompletion":3911,"completion":3911,"start":3912,"enrollment":170,"conditions":3913,"interventions":3914},"NCT02960659","Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes",[86,87],"2022-05-20","2017-05-09",[32],[3899,2172],{"trials":3916,"activeCount":98},[],{"trials":3918,"activeCount":98},[],{"trials":3920,"activeCount":98},[],{"intervention":3922,"totalTrials":94,"cells":3923},"ISIS 304801",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3925,"activeCount":98},[],{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[3930],{"nctId":3931,"briefTitle":3932,"status":148,"phases":3933,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":122,"conditions":3936,"interventions":3937},"NCT02639286","Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension",[87],"2019-09-26","2015-12-23",[34],[3922],{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[],{"trials":3943,"activeCount":98},[],{"intervention":3945,"totalTrials":94,"cells":3946},"Anti-Thymocyte Globulin",{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3948,"activeCount":98},[],{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[3953],{"nctId":3954,"briefTitle":3955,"status":148,"phases":3956,"primaryCompletion":3957,"completion":3958,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3962},"NCT02215200","ATG-GCSF in New Onset Type 1 Diabetes",[87],"2017-08","2018-08","2014-12",89,[452],[3945,3963],"Granulocyte colony stimulating factor",{"trials":3965,"activeCount":98},[],{"trials":3967,"activeCount":98},[],{"trials":3969,"activeCount":98},[],{"intervention":3963,"totalTrials":94,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":98},[],{"trials":3975,"activeCount":98},[],{"trials":3977,"activeCount":98},[3978],{"nctId":3954,"briefTitle":3955,"status":148,"phases":3979,"primaryCompletion":3957,"completion":3958,"start":3959,"enrollment":3960,"conditions":3980,"interventions":3981},[87],[452],[3945,3963],{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[],{"trials":3987,"activeCount":98},[],{"intervention":3989,"totalTrials":94,"cells":3990},"Gamma Interferon 1b",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4004,"PHASE4":4006,"NA":4008},{"trials":3992,"activeCount":98},[],{"trials":3994,"activeCount":98},[],{"trials":3996,"activeCount":98},[3997],{"nctId":3998,"briefTitle":3999,"status":148,"phases":4000,"completion":4001,"start":1114,"enrollment":270,"conditions":4002,"interventions":4003},"NCT00028275","Gamma Interferon Therapy for Chronic Hepatitis C",[87],"2003-11",[997],[3989],{"trials":4005,"activeCount":98},[],{"trials":4007,"activeCount":98},[],{"trials":4009,"activeCount":98},[],{"intervention":4011,"totalTrials":94,"cells":4012},"Vitamin E 200 IU\u002Fd",{"EARLY_PHASE1":4013,"PHASE1":4015,"PHASE2":4017,"PHASE3":4030,"PHASE4":4032,"NA":4034},{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":98},[4019],{"nctId":4020,"briefTitle":4021,"status":148,"phases":4022,"primaryCompletion":4023,"completion":4023,"start":4024,"enrollment":2964,"conditions":4025,"interventions":4027},"NCT01792115","Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E",[87],"2019-08-30","2013-05-01",[4026],"Fatty Liver",[4011,4028,4029],"Vitamin E 400 IU\u002Fd","Vitamin E 800 IU\u002Fd",{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[],{"intervention":4028,"totalTrials":94,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4039,"activeCount":98},[],{"trials":4041,"activeCount":98},[],{"trials":4043,"activeCount":98},[4044],{"nctId":4020,"briefTitle":4021,"status":148,"phases":4045,"primaryCompletion":4023,"completion":4023,"start":4024,"enrollment":2964,"conditions":4046,"interventions":4047},[87],[4026],[4011,4028,4029],{"trials":4049,"activeCount":98},[],{"trials":4051,"activeCount":98},[],{"trials":4053,"activeCount":98},[],{"intervention":4029,"totalTrials":94,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4066,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":98},[],{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[4062],{"nctId":4020,"briefTitle":4021,"status":148,"phases":4063,"primaryCompletion":4023,"completion":4023,"start":4024,"enrollment":2964,"conditions":4064,"interventions":4065},[87],[4026],[4011,4028,4029],{"trials":4067,"activeCount":98},[],{"trials":4069,"activeCount":98},[],{"trials":4071,"activeCount":98},[],{"intervention":3064,"totalTrials":94,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4075,"activeCount":98},[],{"trials":4077,"activeCount":98},[],{"trials":4079,"activeCount":98},[4080],{"nctId":3055,"briefTitle":3056,"status":447,"phases":4081,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":981,"conditions":4082,"interventions":4083},[87],[3050,3061],[3063,3064,3037,3065,3066],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[],{"intervention":3065,"totalTrials":94,"cells":4091},{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4096,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4093,"activeCount":98},[],{"trials":4095,"activeCount":98},[],{"trials":4097,"activeCount":98},[4098],{"nctId":3055,"briefTitle":3056,"status":447,"phases":4099,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":981,"conditions":4100,"interventions":4101},[87],[3050,3061],[3063,3064,3037,3065,3066],{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[],{"intervention":3066,"totalTrials":94,"cells":4109},{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4114,"PHASE3":4120,"PHASE4":4122,"NA":4124},{"trials":4111,"activeCount":98},[],{"trials":4113,"activeCount":98},[],{"trials":4115,"activeCount":98},[4116],{"nctId":3055,"briefTitle":3056,"status":447,"phases":4117,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":981,"conditions":4118,"interventions":4119},[87],[3050,3061],[3063,3064,3037,3065,3066],{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"trials":4125,"activeCount":98},[],{"intervention":4127,"totalTrials":94,"cells":4128},"Parathyroid hormone-related protein or ''PTHrP''",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4130,"activeCount":98},[],{"trials":4132,"activeCount":98},[],{"trials":4134,"activeCount":98},[4135],{"nctId":4136,"briefTitle":4137,"status":148,"phases":4138,"completion":1114,"start":4139,"conditions":4140,"interventions":4141},"NCT00021827","PTHrP and Osteoporosis",[87],"1999-06",[1627],[4127],{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"intervention":4149,"totalTrials":94,"cells":4150},"Anti-CD20",{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4167,"PHASE4":4169,"NA":4171},{"trials":4152,"activeCount":98},[],{"trials":4154,"activeCount":98},[],{"trials":4156,"activeCount":98},[4157],{"nctId":4158,"briefTitle":4159,"status":148,"phases":4160,"primaryCompletion":4161,"completion":4162,"start":4163,"enrollment":4164,"conditions":4165,"interventions":4166},"NCT00279305","Rituximab in New Onset Type 1 Diabetes",[87],"2009-04","2009-11","2005-08",87,[427],[4149],{"trials":4168,"activeCount":98},[],{"trials":4170,"activeCount":98},[],{"trials":4172,"activeCount":98},[],{"intervention":4174,"totalTrials":94,"cells":4175},"Ciprofloxacin",{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4177,"activeCount":98},[],{"trials":4179,"activeCount":98},[],{"trials":4181,"activeCount":98},[4182],{"nctId":4183,"briefTitle":4184,"status":148,"phases":4185,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4189,"interventions":4191},"NCT04552431","Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin",[87],"2003-08-31","1997-09-30",196,[4190],"Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[4174,4192,4193,4194],"Tamsulosin Hydrochloride","Tamsulosin Hydrochloride Placebo","Ciprofloxacin placebo",{"trials":4196,"activeCount":98},[],{"trials":4198,"activeCount":98},[],{"trials":4200,"activeCount":98},[],{"intervention":4192,"totalTrials":94,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4204,"activeCount":98},[],{"trials":4206,"activeCount":98},[],{"trials":4208,"activeCount":98},[4209],{"nctId":4183,"briefTitle":4184,"status":148,"phases":4210,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4211,"interventions":4212},[87],[4190],[4174,4192,4193,4194],{"trials":4214,"activeCount":98},[],{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"intervention":4193,"totalTrials":94,"cells":4220},{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4222,"activeCount":98},[],{"trials":4224,"activeCount":98},[],{"trials":4226,"activeCount":98},[4227],{"nctId":4183,"briefTitle":4184,"status":148,"phases":4228,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4229,"interventions":4230},[87],[4190],[4174,4192,4193,4194],{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[],{"trials":4236,"activeCount":98},[],{"intervention":4194,"totalTrials":94,"cells":4238},{"EARLY_PHASE1":4239,"PHASE1":4241,"PHASE2":4243,"PHASE3":4249,"PHASE4":4251,"NA":4253},{"trials":4240,"activeCount":98},[],{"trials":4242,"activeCount":98},[],{"trials":4244,"activeCount":98},[4245],{"nctId":4183,"briefTitle":4184,"status":148,"phases":4246,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4247,"interventions":4248},[87],[4190],[4174,4192,4193,4194],{"trials":4250,"activeCount":98},[],{"trials":4252,"activeCount":98},[],{"trials":4254,"activeCount":98},[],{"intervention":4256,"totalTrials":94,"cells":4257},"Azathioprine weight-based dose",{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[4264],{"nctId":4265,"briefTitle":4266,"status":447,"phases":4267,"primaryCompletion":2097,"completion":2097,"start":4268,"enrollment":571,"conditions":4269,"interventions":4271},"NCT00113503","Imuran Dosing in Crohn's Disease Study",[87],"2005-07",[4270],"Crohn's Disease",[4256,4272],"Azathioprine individualised dose",{"trials":4274,"activeCount":98},[],{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"intervention":4272,"totalTrials":94,"cells":4280},{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[4287],{"nctId":4265,"briefTitle":4266,"status":447,"phases":4288,"primaryCompletion":2097,"completion":2097,"start":4268,"enrollment":571,"conditions":4289,"interventions":4290},[87],[4270],[4256,4272],{"trials":4292,"activeCount":98},[],{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[],{"intervention":4298,"totalTrials":94,"cells":4299},"Aprepitant",{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4315,"PHASE4":4317,"NA":4319},{"trials":4301,"activeCount":98},[],{"trials":4303,"activeCount":98},[],{"trials":4305,"activeCount":98},[4306],{"nctId":4307,"briefTitle":4308,"status":148,"phases":4309,"primaryCompletion":4310,"completion":1739,"start":3329,"enrollment":4311,"conditions":4312,"interventions":4314},"NCT01149369","Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial",[87],"2015-08",126,[4313],"Gastroparesis",[4298],{"trials":4316,"activeCount":98},[],{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"intervention":4322,"totalTrials":94,"cells":4323},"67.5 mg oral insulin crystals daily",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4325,"activeCount":98},[],{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[4330],{"nctId":4331,"briefTitle":4332,"status":148,"phases":4333,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":4336,"conditions":4337,"interventions":4338},"NCT02580877","Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)",[87],"2018-03","2016-01",92,[3200],[4322,4339],"500mg oral insulin crystals every other week",{"trials":4341,"activeCount":98},[],{"trials":4343,"activeCount":98},[],{"trials":4345,"activeCount":98},[],{"intervention":4339,"totalTrials":94,"cells":4347},{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4358,"PHASE4":4360,"NA":4362},{"trials":4349,"activeCount":98},[],{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[4354],{"nctId":4331,"briefTitle":4332,"status":148,"phases":4355,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":4336,"conditions":4356,"interventions":4357},[87],[3200],[4322,4339],{"trials":4359,"activeCount":98},[],{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[],{"intervention":4365,"totalTrials":94,"cells":4366},"Mycophenolate mofeteil",{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4368,"activeCount":98},[],{"trials":4370,"activeCount":98},[],{"trials":4372,"activeCount":98},[4373],{"nctId":4374,"briefTitle":4375,"status":148,"phases":4376,"primaryCompletion":2026,"completion":2026,"start":2167,"enrollment":4311,"conditions":4377,"interventions":4378},"NCT00100178","New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial",[87],[452],[4365,4379],"Daclizumab",{"trials":4381,"activeCount":98},[],{"trials":4383,"activeCount":98},[],{"trials":4385,"activeCount":98},[],{"intervention":4379,"totalTrials":94,"cells":4387},{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4392,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4389,"activeCount":98},[],{"trials":4391,"activeCount":98},[],{"trials":4393,"activeCount":98},[4394],{"nctId":4374,"briefTitle":4375,"status":148,"phases":4395,"primaryCompletion":2026,"completion":2026,"start":2167,"enrollment":4311,"conditions":4396,"interventions":4397},[87],[452],[4365,4379],{"trials":4399,"activeCount":98},[],{"trials":4401,"activeCount":98},[],{"trials":4403,"activeCount":98},[],{"intervention":2871,"totalTrials":94,"cells":4405},{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4407,"activeCount":98},[],{"trials":4409,"activeCount":98},[],{"trials":4411,"activeCount":98},[4412],{"nctId":2864,"briefTitle":2865,"status":148,"phases":4413,"primaryCompletion":2867,"completion":2867,"start":2420,"enrollment":1651,"conditions":4414,"interventions":4415},[87],[2869],[2836,2871],{"trials":4417,"activeCount":98},[],{"trials":4419,"activeCount":98},[],{"trials":4421,"activeCount":98},[],{"intervention":4423,"totalTrials":94,"cells":4424},"Hydrocortisone",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4443,"PHASE4":4445,"NA":4447},{"trials":4426,"activeCount":98},[],{"trials":4428,"activeCount":98},[],{"trials":4430,"activeCount":98},[4431],{"nctId":4432,"briefTitle":4433,"status":148,"phases":4434,"primaryCompletion":4435,"completion":4436,"start":4437,"enrollment":4438,"conditions":4439,"interventions":4441},"NCT00097474","Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag",[87],"2006-01-06","2007-11-14","2004-12-21",57,[4440],"Jet Lag",[4423,4442],"Melatonin",{"trials":4444,"activeCount":98},[],{"trials":4446,"activeCount":98},[],{"trials":4448,"activeCount":98},[],{"intervention":4442,"totalTrials":94,"cells":4450},{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4455,"PHASE3":4461,"PHASE4":4463,"NA":4465},{"trials":4452,"activeCount":98},[],{"trials":4454,"activeCount":98},[],{"trials":4456,"activeCount":98},[4457],{"nctId":4432,"briefTitle":4433,"status":148,"phases":4458,"primaryCompletion":4435,"completion":4436,"start":4437,"enrollment":4438,"conditions":4459,"interventions":4460},[87],[4440],[4423,4442],{"trials":4462,"activeCount":98},[],{"trials":4464,"activeCount":98},[],{"trials":4466,"activeCount":98},[],{"intervention":2878,"totalTrials":94,"cells":4468},{"EARLY_PHASE1":4469,"PHASE1":4471,"PHASE2":4473,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4470,"activeCount":98},[],{"trials":4472,"activeCount":98},[],{"trials":4474,"activeCount":98},[4475],{"nctId":2873,"briefTitle":2874,"status":148,"phases":4476,"primaryCompletion":2097,"completion":2097,"start":1336,"enrollment":35,"conditions":4477,"interventions":4478},[87],[2003],[2836,2878],{"trials":4480,"activeCount":98},[],{"trials":4482,"activeCount":98},[],{"trials":4484,"activeCount":98},[],{"intervention":4486,"totalTrials":94,"cells":4487},"S-adenosyl-methionine (SAMe)",{"EARLY_PHASE1":4488,"PHASE1":4490,"PHASE2":4492,"PHASE3":4503,"PHASE4":4505,"NA":4507},{"trials":4489,"activeCount":98},[],{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[4494],{"nctId":4495,"briefTitle":4496,"status":447,"phases":4497,"primaryCompletion":4498,"completion":4499,"start":4500,"enrollment":571,"conditions":4501,"interventions":4502},"NCT00125281","SAMe to Treat Biliary Cirrhosis Symptoms",[87],"2007-07-31","2008-07-02","2005-07-25",[1179],[4486],{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[],{"trials":4508,"activeCount":98},[],{"intervention":4510,"totalTrials":94,"cells":4511},"BG9588",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4525,"PHASE4":4527,"NA":4529},{"trials":4513,"activeCount":98},[],{"trials":4515,"activeCount":98},[],{"trials":4517,"activeCount":98},[4518],{"nctId":4519,"briefTitle":4520,"status":148,"phases":4521,"completion":268,"start":4522,"enrollment":571,"conditions":4523,"interventions":4524},"NCT00001857","Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation",[87],"1999-05",[2869],[4510],{"trials":4526,"activeCount":98},[],{"trials":4528,"activeCount":98},[],{"trials":4530,"activeCount":98},[],{"intervention":2956,"totalTrials":94,"cells":4532},{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4537,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[],{"trials":4538,"activeCount":98},[4539],{"nctId":2948,"briefTitle":2949,"status":148,"phases":4540,"primaryCompletion":2951,"completion":2952,"start":2953,"enrollment":19,"conditions":4541,"interventions":4542},[87],[2423,2945],[2956,2930,2957],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[],{"trials":4548,"activeCount":98},[],{"intervention":3001,"totalTrials":94,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4552,"activeCount":98},[],{"trials":4554,"activeCount":98},[],{"trials":4556,"activeCount":98},[4557],{"nctId":2991,"briefTitle":2992,"status":148,"phases":4558,"completion":2910,"start":2994,"enrollment":2995,"conditions":4559,"interventions":4560},[87],[295,2997],[2999,3000,3001],{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[],{"trials":4566,"activeCount":98},[],{"intervention":4568,"totalTrials":94,"cells":4569},"Pantoprazole",{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4574,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4571,"activeCount":98},[],{"trials":4573,"activeCount":98},[],{"trials":4575,"activeCount":98},[4576],{"nctId":4577,"briefTitle":4578,"status":148,"phases":4579,"completion":4580,"start":4581,"conditions":4582,"interventions":4584},"NCT00001191","The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid",[87],"2007-12-10","1983-02-03",[4583,3565],"Gastrinoma",[4568,4585],"Omeprazole",{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[],{"intervention":4585,"totalTrials":94,"cells":4593},{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4604,"PHASE4":4606,"NA":4608},{"trials":4595,"activeCount":98},[],{"trials":4597,"activeCount":98},[],{"trials":4599,"activeCount":98},[4600],{"nctId":4577,"briefTitle":4578,"status":148,"phases":4601,"completion":4580,"start":4581,"conditions":4602,"interventions":4603},[87],[4583,3565],[4568,4585],{"trials":4605,"activeCount":98},[],{"trials":4607,"activeCount":98},[],{"trials":4609,"activeCount":98},[],{"intervention":4611,"totalTrials":94,"cells":4612},"5-Azacytidine",{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4617,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4614,"activeCount":98},[],{"trials":4616,"activeCount":98},[],{"trials":4618,"activeCount":98},[4619],{"nctId":4620,"briefTitle":4621,"status":148,"phases":4622,"completion":1519,"start":1096,"enrollment":170,"conditions":4623,"interventions":4625},"NCT00005934","5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia",[87],[4624],"Beta Thalassemia",[4611],{"trials":4627,"activeCount":98},[],{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[],{"intervention":4633,"totalTrials":94,"cells":4634},"obeticholic acid",{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4639,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4636,"activeCount":98},[],{"trials":4638,"activeCount":98},[],{"trials":4640,"activeCount":98},[4641],{"nctId":4642,"briefTitle":4643,"status":148,"phases":4644,"primaryCompletion":4645,"completion":4646,"start":3058,"enrollment":4647,"conditions":4648,"interventions":4650},"NCT01265498","The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)",[87],"2014-01","2014-09",283,[1743,4649],"Nonalcoholic Steatohepatitis (NASH)",[4633],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"trials":4656,"activeCount":98},[],{"intervention":4658,"totalTrials":94,"cells":4659},"Propranolol",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4661,"activeCount":98},[],{"trials":4663,"activeCount":98},[],{"trials":4665,"activeCount":98},[4666],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4669,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4674,"interventions":4675},"NCT01950520","Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate",[87],"2022-12-17","2024-06-11","2014-02-07",47,[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],"Pindolol","Dantrolene","Magnesium Sulfate","Caffeine","Qsymia","Topiramate","Naltrexone","Mirabegron 50mg","Mirabegron 200mg",{"trials":4686,"activeCount":98},[],{"trials":4688,"activeCount":98},[],{"trials":4690,"activeCount":98},[],{"intervention":4676,"totalTrials":94,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4694,"activeCount":98},[],{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[4699],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4700,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4701,"interventions":4702},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4704,"activeCount":98},[],{"trials":4706,"activeCount":98},[],{"trials":4708,"activeCount":98},[],{"intervention":4677,"totalTrials":94,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":98},[],{"trials":4714,"activeCount":98},[],{"trials":4716,"activeCount":98},[4717],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4718,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4719,"interventions":4720},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4722,"activeCount":98},[],{"trials":4724,"activeCount":98},[],{"trials":4726,"activeCount":98},[],{"intervention":4678,"totalTrials":94,"cells":4728},{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4730,"activeCount":98},[],{"trials":4732,"activeCount":98},[],{"trials":4734,"activeCount":98},[4735],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4736,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4737,"interventions":4738},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4740,"activeCount":98},[],{"trials":4742,"activeCount":98},[],{"trials":4744,"activeCount":98},[],{"intervention":4679,"totalTrials":94,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4748,"activeCount":98},[],{"trials":4750,"activeCount":98},[],{"trials":4752,"activeCount":98},[4753],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4754,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4755,"interventions":4756},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4758,"activeCount":98},[],{"trials":4760,"activeCount":98},[],{"trials":4762,"activeCount":98},[],{"intervention":4680,"totalTrials":94,"cells":4764},{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4766,"activeCount":98},[],{"trials":4768,"activeCount":98},[],{"trials":4770,"activeCount":98},[4771],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4772,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4773,"interventions":4774},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4776,"activeCount":98},[],{"trials":4778,"activeCount":98},[],{"trials":4780,"activeCount":98},[],{"intervention":4681,"totalTrials":94,"cells":4782},{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4787,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4784,"activeCount":98},[],{"trials":4786,"activeCount":98},[],{"trials":4788,"activeCount":98},[4789],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4790,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4791,"interventions":4792},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4794,"activeCount":98},[],{"trials":4796,"activeCount":98},[],{"trials":4798,"activeCount":98},[],{"intervention":4682,"totalTrials":94,"cells":4800},{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4805,"PHASE3":4811,"PHASE4":4813,"NA":4815},{"trials":4802,"activeCount":98},[],{"trials":4804,"activeCount":98},[],{"trials":4806,"activeCount":98},[4807],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4808,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4809,"interventions":4810},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4812,"activeCount":98},[],{"trials":4814,"activeCount":98},[],{"trials":4816,"activeCount":98},[],{"intervention":4683,"totalTrials":94,"cells":4818},{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4823,"PHASE3":4829,"PHASE4":4831,"NA":4833},{"trials":4820,"activeCount":98},[],{"trials":4822,"activeCount":98},[],{"trials":4824,"activeCount":98},[4825],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4826,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4827,"interventions":4828},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4830,"activeCount":98},[],{"trials":4832,"activeCount":98},[],{"trials":4834,"activeCount":98},[],{"intervention":4684,"totalTrials":94,"cells":4836},{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4847,"PHASE4":4849,"NA":4851},{"trials":4838,"activeCount":98},[],{"trials":4840,"activeCount":98},[],{"trials":4842,"activeCount":98},[4843],{"nctId":4667,"briefTitle":4668,"status":148,"phases":4844,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4845,"interventions":4846},[87],[21],[4658,4676,4677,4678,4679,4680,4681,4682,4683,4684],{"trials":4848,"activeCount":98},[],{"trials":4850,"activeCount":98},[],{"trials":4852,"activeCount":98},[],{"intervention":4854,"totalTrials":94,"cells":4855},"losartan 100 mg orally once daily",{"EARLY_PHASE1":4856,"PHASE1":4858,"PHASE2":4860,"PHASE3":4870,"PHASE4":4872,"NA":4874},{"trials":4857,"activeCount":98},[],{"trials":4859,"activeCount":98},[],{"trials":4861,"activeCount":98},[4862],{"nctId":4863,"briefTitle":4864,"status":148,"phases":4865,"completion":1257,"start":2612,"enrollment":4336,"conditions":4866,"interventions":4868},"NCT00381134","Improving Outcomes in Patients With Kidney Disease Due to Diabetes",[87],[18,4867,2920],"Kidney Disease",[4854,4869],"spironolactone 25 mg orally once daily",{"trials":4871,"activeCount":98},[],{"trials":4873,"activeCount":98},[],{"trials":4875,"activeCount":98},[],{"intervention":4869,"totalTrials":94,"cells":4877},{"EARLY_PHASE1":4878,"PHASE1":4880,"PHASE2":4882,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4879,"activeCount":98},[],{"trials":4881,"activeCount":98},[],{"trials":4883,"activeCount":98},[4884],{"nctId":4863,"briefTitle":4864,"status":148,"phases":4885,"completion":1257,"start":2612,"enrollment":4336,"conditions":4886,"interventions":4887},[87],[18,4867,2920],[4854,4869],{"trials":4889,"activeCount":98},[],{"trials":4891,"activeCount":98},[],{"trials":4893,"activeCount":98},[],{"intervention":4895,"totalTrials":94,"cells":4896},"Tobramycin for Inhalation",{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4912,"PHASE4":4914,"NA":4916},{"trials":4898,"activeCount":98},[],{"trials":4900,"activeCount":98},[],{"trials":4902,"activeCount":98},[4903],{"nctId":4904,"briefTitle":4905,"status":148,"phases":4906,"completion":4907,"start":4908,"enrollment":4909,"conditions":4910,"interventions":4911},"NCT00006280","A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis",[87],"2002-02","2000-02",98,[2101],[4895],{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"intervention":4919,"totalTrials":94,"cells":4920},"Peginterferon Lambda",{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4935,"PHASE4":4937,"NA":4939},{"trials":4922,"activeCount":98},[],{"trials":4924,"activeCount":98},[],{"trials":4926,"activeCount":98},[4927],{"nctId":4928,"briefTitle":4929,"status":476,"phases":4930,"primaryCompletion":4931,"completion":4931,"start":4931,"enrollment":98,"conditions":4932,"interventions":4934},"NCT05953545","Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis",[87],"2024-05-22",[4933],"Chronic Hepatitis Delta",[4919],{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[],{"trials":4940,"activeCount":98},[],{"intervention":4942,"totalTrials":94,"cells":4943},"1 alpha D2",{"EARLY_PHASE1":4944,"PHASE1":4946,"PHASE2":4948,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4945,"activeCount":98},[],{"trials":4947,"activeCount":98},[],{"trials":4949,"activeCount":98},[4950],{"nctId":4951,"briefTitle":4952,"status":148,"phases":4953,"completion":2725,"start":1152,"enrollment":4954,"conditions":4955,"interventions":4958},"NCT00560300","Regulation of Bone Formation in Renal Osteodystrophy",[87],61,[4956,4957],"Secondary Hyperparathyroidism","Renal Osteodystrophy",[4942,4959,4960,4961],"1,25 dihydroxy vitamin D3","Sevelamer HCl","Calcium Carbonate",{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[],{"trials":4967,"activeCount":98},[],{"intervention":4959,"totalTrials":94,"cells":4969},{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4974,"PHASE3":4980,"PHASE4":4982,"NA":4984},{"trials":4971,"activeCount":98},[],{"trials":4973,"activeCount":98},[],{"trials":4975,"activeCount":98},[4976],{"nctId":4951,"briefTitle":4952,"status":148,"phases":4977,"completion":2725,"start":1152,"enrollment":4954,"conditions":4978,"interventions":4979},[87],[4956,4957],[4942,4959,4960,4961],{"trials":4981,"activeCount":98},[],{"trials":4983,"activeCount":98},[],{"trials":4985,"activeCount":98},[],{"intervention":4960,"totalTrials":94,"cells":4987},{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4992,"PHASE3":4998,"PHASE4":5000,"NA":5002},{"trials":4989,"activeCount":98},[],{"trials":4991,"activeCount":98},[],{"trials":4993,"activeCount":98},[4994],{"nctId":4951,"briefTitle":4952,"status":148,"phases":4995,"completion":2725,"start":1152,"enrollment":4954,"conditions":4996,"interventions":4997},[87],[4956,4957],[4942,4959,4960,4961],{"trials":4999,"activeCount":98},[],{"trials":5001,"activeCount":98},[],{"trials":5003,"activeCount":98},[],{"intervention":4961,"totalTrials":94,"cells":5005},{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5007,"activeCount":98},[],{"trials":5009,"activeCount":98},[],{"trials":5011,"activeCount":98},[5012],{"nctId":4951,"briefTitle":4952,"status":148,"phases":5013,"completion":2725,"start":1152,"enrollment":4954,"conditions":5014,"interventions":5015},[87],[4956,4957],[4942,4959,4960,4961],{"trials":5017,"activeCount":98},[],{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[],{"intervention":5023,"totalTrials":94,"cells":5024},"TRH",{"EARLY_PHASE1":5025,"PHASE1":5027,"PHASE2":5029,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[],{"trials":5030,"activeCount":98},[5031],{"nctId":5032,"briefTitle":5033,"status":148,"phases":5034,"primaryCompletion":5035,"completion":5035,"start":5036,"enrollment":3021,"conditions":5037,"interventions":5041},"NCT00054756","Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities",[87],"2014-09-26","2003-02-07",[5038,5039,5040],"Healthy","Pituitary Disease","Thyroid Disease",[5023],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"trials":5047,"activeCount":98},[],{"intervention":5049,"totalTrials":94,"cells":5050},"Sofosbuvir",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5066,"PHASE4":5068,"NA":5070},{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[],{"trials":5056,"activeCount":98},[5057],{"nctId":5058,"briefTitle":5059,"status":148,"phases":5060,"primaryCompletion":5061,"completion":5061,"start":5062,"enrollment":9,"conditions":5063,"interventions":5064},"NCT02468648","Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816",[87],"2018-09-14","2015-06-09",[997],[5049,5065],"GS-5816",{"trials":5067,"activeCount":98},[],{"trials":5069,"activeCount":98},[],{"trials":5071,"activeCount":98},[],{"intervention":5065,"totalTrials":94,"cells":5073},{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5075,"activeCount":98},[],{"trials":5077,"activeCount":98},[],{"trials":5079,"activeCount":98},[5080],{"nctId":5058,"briefTitle":5059,"status":148,"phases":5081,"primaryCompletion":5061,"completion":5061,"start":5062,"enrollment":9,"conditions":5082,"interventions":5083},[87],[997],[5049,5065],{"trials":5085,"activeCount":98},[],{"trials":5087,"activeCount":98},[],{"trials":5089,"activeCount":98},[],{"intervention":5091,"totalTrials":94,"cells":5092},"Pirfenidone",{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5097,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5094,"activeCount":98},[],{"trials":5096,"activeCount":98},[],{"trials":5098,"activeCount":98},[5099],{"nctId":5100,"briefTitle":5101,"status":148,"phases":5102,"primaryCompletion":5103,"completion":5103,"start":3514,"enrollment":995,"conditions":5104,"interventions":5105},"NCT00001959","Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)",[87],"2008-10",[1029,2861,2003,295,487],[5091],{"trials":5107,"activeCount":98},[],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[],{"intervention":5113,"totalTrials":94,"cells":5114},"immunosuppressive regimen designed to complement HAART",{"EARLY_PHASE1":5115,"PHASE1":5117,"PHASE2":5119,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5116,"activeCount":98},[],{"trials":5118,"activeCount":98},[],{"trials":5120,"activeCount":98},[5121],{"nctId":5122,"briefTitle":5123,"status":148,"phases":5124,"completion":2237,"start":5125,"enrollment":5126,"conditions":5127,"interventions":5130},"NCT00009009","Kidney Transplant for HIV-Infected Patients in Renal Failure",[87],"2001-01",10,[5128,5129],"Chronic Kidney Failure","HIV Infection",[5113],{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"intervention":5138,"totalTrials":94,"cells":5139},"Isotretinoin",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5141,"activeCount":98},[],{"trials":5143,"activeCount":98},[],{"trials":5145,"activeCount":98},[5146],{"nctId":5147,"briefTitle":5148,"status":148,"phases":5149,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":35,"conditions":5152,"interventions":5155},"NCT00098020","Podocyte Retinoids",[87],"2016-06-27","2004-11-26",[5153,5154],"Collapsing Glomerulopathy","Glomerulosclerosis, Focal Segmental",[5138],{"trials":5157,"activeCount":98},[],{"trials":5159,"activeCount":98},[],{"trials":5161,"activeCount":98},[],{"intervention":323,"totalTrials":94,"cells":5163},{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5165,"activeCount":98},[],{"trials":5167,"activeCount":98},[],{"trials":5169,"activeCount":98},[5170],{"nctId":310,"briefTitle":311,"status":148,"phases":5171,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":5172,"interventions":5173},[87],[317,318,319,320,321],[323,324,325,278],{"trials":5175,"activeCount":98},[],{"trials":5177,"activeCount":98},[],{"trials":5179,"activeCount":98},[],{"intervention":324,"totalTrials":94,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5192,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":98},[],{"trials":5185,"activeCount":98},[],{"trials":5187,"activeCount":98},[5188],{"nctId":310,"briefTitle":311,"status":148,"phases":5189,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":5190,"interventions":5191},[87],[317,318,319,320,321],[323,324,325,278],{"trials":5193,"activeCount":98},[],{"trials":5195,"activeCount":98},[],{"trials":5197,"activeCount":98},[],{"intervention":325,"totalTrials":94,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5210,"PHASE4":5212,"NA":5214},{"trials":5201,"activeCount":98},[],{"trials":5203,"activeCount":98},[],{"trials":5205,"activeCount":98},[5206],{"nctId":310,"briefTitle":311,"status":148,"phases":5207,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":5208,"interventions":5209},[87],[317,318,319,320,321],[323,324,325,278],{"trials":5211,"activeCount":98},[],{"trials":5213,"activeCount":98},[],{"trials":5215,"activeCount":98},[],{"intervention":5217,"totalTrials":94,"cells":5218},"Buprenorphine",{"EARLY_PHASE1":5219,"PHASE1":5221,"PHASE2":5223,"PHASE3":5238,"PHASE4":5240,"NA":5242},{"trials":5220,"activeCount":98},[],{"trials":5222,"activeCount":98},[],{"trials":5224,"activeCount":98},[5225],{"nctId":5226,"briefTitle":5227,"status":148,"phases":5228,"primaryCompletion":5229,"completion":5230,"start":5231,"enrollment":5232,"conditions":5233,"interventions":5237},"NCT04571619","HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis",[87],"2023-12-21","2024-05-31","2021-01-03",643,[5234,5235,5236],"End Stage Renal Disease","Chronic Pain","Opioid Dependence",[5217],{"trials":5239,"activeCount":98},[],{"trials":5241,"activeCount":98},[],{"trials":5243,"activeCount":98},[],{"intervention":5245,"totalTrials":94,"cells":5246},"Polyunsaturated fatty acid",{"EARLY_PHASE1":5247,"PHASE1":5249,"PHASE2":5251,"PHASE3":5260,"PHASE4":5262,"NA":5264},{"trials":5248,"activeCount":98},[],{"trials":5250,"activeCount":98},[],{"trials":5252,"activeCount":98},[5253],{"nctId":5254,"briefTitle":5255,"status":148,"phases":5256,"primaryCompletion":2943,"completion":2943,"start":3357,"enrollment":5257,"conditions":5258,"interventions":5259},"NCT00323414","Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver",[87],37,[4026],[5245],{"trials":5261,"activeCount":98},[],{"trials":5263,"activeCount":98},[],{"trials":5265,"activeCount":98},[],{"intervention":5267,"totalTrials":94,"cells":5268},"DUAL",{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[],{"trials":5274,"activeCount":98},[5275],{"nctId":5276,"briefTitle":5277,"status":148,"phases":5278,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":1544,"conditions":5281,"interventions":5282},"NCT01888900","New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C",[87],"2015-11","2013-05",[540,997,1040,116],[5267,5283],"QUAD",{"trials":5285,"activeCount":98},[],{"trials":5287,"activeCount":98},[],{"trials":5289,"activeCount":98},[],{"intervention":5283,"totalTrials":94,"cells":5291},{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5293,"activeCount":98},[],{"trials":5295,"activeCount":98},[],{"trials":5297,"activeCount":98},[5298],{"nctId":5276,"briefTitle":5277,"status":148,"phases":5299,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":1544,"conditions":5300,"interventions":5301},[87],[540,997,1040,116],[5267,5283],{"trials":5303,"activeCount":98},[],{"trials":5305,"activeCount":98},[],{"trials":5307,"activeCount":98},[],{"intervention":5309,"totalTrials":94,"cells":5310},"Golimumab",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5325,"PHASE4":5327,"NA":5329},{"trials":5312,"activeCount":98},[],{"trials":5314,"activeCount":98},[],{"trials":5316,"activeCount":98},[5317],{"nctId":5318,"briefTitle":5319,"status":476,"phases":5320,"primaryCompletion":5321,"completion":5321,"start":5322,"enrollment":98,"conditions":5323,"interventions":5324},"NCT04729296","Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D",[87],"2027-07-01","2021-07-01",[452],[5309],{"trials":5326,"activeCount":98},[],{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[],{"intervention":5332,"totalTrials":94,"cells":5333},"Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay",{"EARLY_PHASE1":5334,"PHASE1":5336,"PHASE2":5338,"PHASE3":5348,"PHASE4":5350,"NA":5352},{"trials":5335,"activeCount":98},[],{"trials":5337,"activeCount":98},[],{"trials":5339,"activeCount":98},[5340],{"nctId":5341,"briefTitle":5342,"status":148,"phases":5343,"completion":5344,"start":5345,"enrollment":270,"conditions":5346,"interventions":5347},"NCT00062712","Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients",[87],"2007-03-22","2003-06-09",[2869],[5332],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[],{"trials":5353,"activeCount":98},[],{"intervention":1547,"totalTrials":94,"cells":5355},{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5360,"PHASE3":5366,"PHASE4":5368,"NA":5370},{"trials":5357,"activeCount":98},[],{"trials":5359,"activeCount":98},[],{"trials":5361,"activeCount":98},[5362],{"nctId":1539,"briefTitle":1540,"status":447,"phases":5363,"primaryCompletion":1542,"completion":1542,"start":1543,"enrollment":1544,"conditions":5364,"interventions":5365},[87],[1428],[1547,1530],{"trials":5367,"activeCount":98},[],{"trials":5369,"activeCount":98},[],{"trials":5371,"activeCount":98},[],{"intervention":5373,"totalTrials":94,"cells":5374},"Vitamin E with and without Vitamin C",{"EARLY_PHASE1":5375,"PHASE1":5377,"PHASE2":5379,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5376,"activeCount":98},[],{"trials":5378,"activeCount":98},[],{"trials":5380,"activeCount":98},[5381],{"nctId":5382,"briefTitle":5383,"status":148,"phases":5384,"primaryCompletion":1622,"completion":1622,"start":1957,"enrollment":5385,"conditions":5386,"interventions":5388},"NCT00067899","Oxidative Stress and Vitamin E Requirements",[87],99,[5387],"Smoking",[5373],{"trials":5390,"activeCount":98},[],{"trials":5392,"activeCount":98},[],{"trials":5394,"activeCount":98},[],{"intervention":1018,"totalTrials":94,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5407,"PHASE4":5409,"NA":5411},{"trials":5398,"activeCount":98},[],{"trials":5400,"activeCount":98},[],{"trials":5402,"activeCount":98},[5403],{"nctId":1010,"briefTitle":1011,"status":148,"phases":5404,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":170,"conditions":5405,"interventions":5406},[87],[997],[1017,980,1018],{"trials":5408,"activeCount":98},[],{"trials":5410,"activeCount":98},[],{"trials":5412,"activeCount":98},[],{"intervention":5414,"totalTrials":94,"cells":5415},"Testosterone enanthate",{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5429,"PHASE4":5431,"NA":5433},{"trials":5417,"activeCount":98},[],{"trials":5419,"activeCount":98},[],{"trials":5421,"activeCount":98},[5422],{"nctId":5423,"briefTitle":5424,"status":148,"phases":5425,"primaryCompletion":2637,"completion":2637,"start":3473,"enrollment":4954,"conditions":5426,"interventions":5428},"NCT00260143","Testosterone and Physical Function in HIV+ Men",[87],[5427],"HIV Associate Weight Loss",[5414],{"trials":5430,"activeCount":98},[],{"trials":5432,"activeCount":98},[],{"trials":5434,"activeCount":98},[],{"intervention":5436,"totalTrials":94,"cells":5437},"Methyldopa",{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5453,"PHASE4":5455,"NA":5457},{"trials":5439,"activeCount":98},[],{"trials":5441,"activeCount":98},[],{"trials":5443,"activeCount":98},[5444],{"nctId":5445,"briefTitle":5446,"status":476,"phases":5447,"primaryCompletion":5448,"completion":5448,"start":5449,"enrollment":98,"conditions":5450,"interventions":5452},"NCT03396484","Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes",[87],"2022-03","2020-09",[5451],"Type1 Diabetes Mellitus",[5436],{"trials":5454,"activeCount":98},[],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[],{"intervention":5460,"totalTrials":94,"cells":5461},"Hydroxychloroquine",{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5478,"PHASE4":5480,"NA":5482},{"trials":5463,"activeCount":98},[],{"trials":5465,"activeCount":98},[],{"trials":5467,"activeCount":98},[5468],{"nctId":5469,"briefTitle":5470,"status":447,"phases":5471,"primaryCompletion":5472,"completion":5473,"start":5474,"enrollment":5475,"conditions":5476,"interventions":5477},"NCT03428945","Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus",[87],"2022-10-27","2022-10-31","2018-08-15",273,[5451],[5460],{"trials":5479,"activeCount":98},[],{"trials":5481,"activeCount":98},[],{"trials":5483,"activeCount":98},[],{"intervention":5485,"totalTrials":94,"cells":5486},"Alemtuzumab and DSG",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5501,"PHASE4":5503,"NA":5505},{"trials":5488,"activeCount":98},[],{"trials":5490,"activeCount":98},[],{"trials":5492,"activeCount":98},[5493],{"nctId":5494,"briefTitle":5495,"status":148,"phases":5496,"primaryCompletion":1857,"completion":1857,"start":5497,"enrollment":122,"conditions":5498,"interventions":5500},"NCT00001984","Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys",[87],"1999-11",[5499,4867],"Graft Rejection",[5485],{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[],{"intervention":5508,"totalTrials":94,"cells":5509},"Hydroxyurea",{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5514,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5511,"activeCount":98},[],{"trials":5513,"activeCount":98},[],{"trials":5515,"activeCount":98},[5516],{"nctId":5517,"briefTitle":5518,"status":148,"phases":5519,"completion":4907,"start":3514,"enrollment":217,"conditions":5520,"interventions":5522},"NCT00001958","Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)",[87],[4624,5521],"Hemoglobinopathy",[5508],{"trials":5524,"activeCount":98},[],{"trials":5526,"activeCount":98},[],{"trials":5528,"activeCount":98},[],{"intervention":5530,"totalTrials":94,"cells":5531},"Intravenous immunoglobulin",{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5536,"PHASE3":5547,"PHASE4":5549,"NA":5551},{"trials":5533,"activeCount":98},[],{"trials":5535,"activeCount":98},[],{"trials":5537,"activeCount":98},[5538],{"nctId":5539,"briefTitle":5540,"status":148,"phases":5541,"primaryCompletion":5542,"completion":5542,"start":5543,"enrollment":256,"conditions":5544,"interventions":5546},"NCT01854827","Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia",[86,87],"2016-07","2013-10",[5545],"Biliary Atresia",[5530],{"trials":5548,"activeCount":98},[],{"trials":5550,"activeCount":98},[],{"trials":5552,"activeCount":98},[],{"intervention":5554,"totalTrials":94,"cells":5555},"Leptin A-100",{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5560,"PHASE3":5569,"PHASE4":5571,"NA":5573},{"trials":5557,"activeCount":98},[],{"trials":5559,"activeCount":98},[],{"trials":5561,"activeCount":98},[5562],{"nctId":5563,"briefTitle":5564,"status":148,"phases":5565,"completion":2237,"start":1151,"enrollment":164,"conditions":5566,"interventions":5568},"NCT00027456","Leptin to Treat Severe Insulin Resistance - Pilot Study",[87],[5567],"Syndrome",[5554],{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"intervention":5576,"totalTrials":94,"cells":5577},"1,25-Dihydroxycholecalciferol",{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5593,"PHASE4":5595,"NA":5597},{"trials":5579,"activeCount":98},[],{"trials":5581,"activeCount":98},[],{"trials":5583,"activeCount":98},[5584],{"nctId":5585,"briefTitle":5586,"status":447,"phases":5587,"primaryCompletion":1095,"completion":1095,"start":5588,"enrollment":1067,"conditions":5589,"interventions":5592},"NCT00001151","Studies With 1,25-Dihydroxycholecalciferol",[87],"1976-03",[5590,5591],"Hypocalcemia","Rickets",[5576],{"trials":5594,"activeCount":98},[],{"trials":5596,"activeCount":98},[],{"trials":5598,"activeCount":98},[],{"intervention":5600,"totalTrials":94,"cells":5601},"Vancomycin",{"EARLY_PHASE1":5602,"PHASE1":5604,"PHASE2":5606,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5603,"activeCount":98},[],{"trials":5605,"activeCount":98},[],{"trials":5607,"activeCount":98},[5608],{"nctId":5609,"briefTitle":5610,"status":148,"phases":5611,"primaryCompletion":5612,"completion":5612,"start":5613,"enrollment":5614,"conditions":5615,"interventions":5616},"NCT02037295","Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans",[87],"2019-03-29","2014-01-14",27,[15],[5600],{"trials":5618,"activeCount":98},[],{"trials":5620,"activeCount":98},[],{"trials":5622,"activeCount":98},[],{"intervention":5624,"totalTrials":94,"cells":5625},"budesonide",{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5639,"PHASE3":5641,"PHASE4":5643,"NA":5645},{"trials":5627,"activeCount":98},[],{"trials":5629,"activeCount":98},[5630],{"nctId":5631,"briefTitle":5632,"status":148,"phases":5633,"primaryCompletion":5634,"completion":5634,"start":5635,"enrollment":2964,"conditions":5636,"interventions":5638},"NCT00004842","Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis",[86],"1999-04","1997-05",[5637,1179],"Cholangitis, Sclerosing",[5624],{"trials":5640,"activeCount":98},[],{"trials":5642,"activeCount":98},[],{"trials":5644,"activeCount":98},[],{"trials":5646,"activeCount":98},[],{"intervention":5648,"totalTrials":94,"cells":5649},"N-acetyl D-mannosamine",{"EARLY_PHASE1":5650,"PHASE1":5652,"PHASE2":5662,"PHASE3":5664,"PHASE4":5666,"NA":5668},{"trials":5651,"activeCount":98},[],{"trials":5653,"activeCount":98},[5654],{"nctId":5655,"briefTitle":5656,"status":148,"phases":5657,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5126,"conditions":5660,"interventions":5661},"NCT02639260","A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases",[86],"2018-06-05","2016-07-07",[4867],[5648],{"trials":5663,"activeCount":98},[],{"trials":5665,"activeCount":98},[],{"trials":5667,"activeCount":98},[],{"trials":5669,"activeCount":98},[],{"intervention":5671,"totalTrials":94,"cells":5672},"Alpha tocopherol",{"EARLY_PHASE1":5673,"PHASE1":5675,"PHASE2":5686,"PHASE3":5688,"PHASE4":5690,"NA":5692},{"trials":5674,"activeCount":98},[],{"trials":5676,"activeCount":98},[5677],{"nctId":5678,"briefTitle":5679,"status":148,"phases":5680,"primaryCompletion":5681,"completion":5682,"start":5683,"enrollment":571,"conditions":5684,"interventions":5685},"NCT00862433","Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women",[86],"2016-10-21","2022-05-03","2014-10-10",[18,4026,15,21],[5671],{"trials":5687,"activeCount":98},[],{"trials":5689,"activeCount":98},[],{"trials":5691,"activeCount":98},[],{"trials":5693,"activeCount":98},[],{"intervention":5695,"totalTrials":94,"cells":5696},"Combination Iron Chelation Therapy",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5707,"PHASE3":5709,"PHASE4":5711,"NA":5713},{"trials":5698,"activeCount":98},[],{"trials":5700,"activeCount":98},[5701],{"nctId":5702,"briefTitle":5695,"status":148,"phases":5703,"completion":1258,"start":5704,"conditions":5705,"interventions":5706},"NCT00004982",[86],"1998-12",[1457,1456],[5695],{"trials":5708,"activeCount":98},[],{"trials":5710,"activeCount":98},[],{"trials":5712,"activeCount":98},[],{"trials":5714,"activeCount":98},[],{"intervention":5716,"totalTrials":94,"cells":5717},"Canagliflozin",{"EARLY_PHASE1":5718,"PHASE1":5720,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5719,"activeCount":98},[],{"trials":5721,"activeCount":98},[5722],{"nctId":5723,"briefTitle":5724,"status":148,"phases":5725,"primaryCompletion":5726,"completion":5727,"start":5728,"enrollment":5729,"conditions":5730,"interventions":5731},"NCT02404870","Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers",[86],"2019-05-01","2019-09-03","2014-09-16",67,[21],[5716],{"trials":5733,"activeCount":98},[],{"trials":5735,"activeCount":98},[],{"trials":5737,"activeCount":98},[],{"trials":5739,"activeCount":98},[],{"intervention":5741,"totalTrials":94,"cells":5742},"stable isotope of iron, dysprosium",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5755,"PHASE3":5757,"PHASE4":5759,"NA":5761},{"trials":5744,"activeCount":98},[],{"trials":5746,"activeCount":98},[5747],{"nctId":5748,"briefTitle":5749,"status":148,"phases":5750,"start":5751,"enrollment":2421,"conditions":5752,"interventions":5754},"NCT00399191","A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia",[86],"2006-08",[5753],"Iron Deficiency Anemia",[5741],{"trials":5756,"activeCount":98},[],{"trials":5758,"activeCount":98},[],{"trials":5760,"activeCount":98},[],{"trials":5762,"activeCount":98},[],{"intervention":5764,"totalTrials":94,"cells":5765},"hokt3g1",{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5777,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5767,"activeCount":98},[],{"trials":5769,"activeCount":98},[5770],{"nctId":5771,"briefTitle":5772,"status":148,"phases":5773,"completion":1622,"start":1519,"enrollment":35,"conditions":5774,"interventions":5776},"NCT00073255","Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)",[86],[5775],"Diabetes Mellitus, Insulin-Dependent",[5764],{"trials":5778,"activeCount":98},[],{"trials":5780,"activeCount":98},[],{"trials":5782,"activeCount":98},[],{"trials":5784,"activeCount":98},[],{"intervention":5786,"totalTrials":94,"cells":5787},"Adeno-associated virus-CFTR vector",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5798,"PHASE3":5800,"PHASE4":5802,"NA":5804},{"trials":5789,"activeCount":98},[],{"trials":5791,"activeCount":98},[5792],{"nctId":5793,"briefTitle":5794,"status":148,"phases":5795,"primaryCompletion":1037,"completion":1037,"start":2588,"enrollment":22,"conditions":5796,"interventions":5797},"NCT00004533","Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis",[86],[2101],[5786],{"trials":5799,"activeCount":98},[],{"trials":5801,"activeCount":98},[],{"trials":5803,"activeCount":98},[],{"trials":5805,"activeCount":98},[],{"intervention":5807,"totalTrials":94,"cells":5808},"Recombinant-methionyl human stem cell factor",{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5822,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5810,"activeCount":98},[],{"trials":5812,"activeCount":98},[5813],{"nctId":5814,"briefTitle":5815,"status":148,"phases":5816,"completion":5817,"start":292,"enrollment":571,"conditions":5818,"interventions":5821},"NCT00005783","A Phase I\u002FII Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders",[86],"2000-10",[5819,5820],"Hemoglobin SC Disease","Sickle Cell Anemia",[5807],{"trials":5823,"activeCount":98},[],{"trials":5825,"activeCount":98},[],{"trials":5827,"activeCount":98},[],{"trials":5829,"activeCount":98},[],{"intervention":5831,"totalTrials":94,"cells":5832},"Peginterferon & Ribavirin for Hepatitis C",{"EARLY_PHASE1":5833,"PHASE1":5835,"PHASE2":5847,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5834,"activeCount":98},[],{"trials":5836,"activeCount":98},[5837],{"nctId":5838,"briefTitle":5839,"status":148,"phases":5840,"completion":5841,"start":5842,"enrollment":5843,"conditions":5844,"interventions":5845},"NCT00718172","Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C",[86],"2014-08-19","2008-07-11",81,[116],[5831,5846],"Pre-treatment Ribavirin",{"trials":5848,"activeCount":98},[],{"trials":5850,"activeCount":98},[],{"trials":5852,"activeCount":98},[],{"trials":5854,"activeCount":98},[],{"intervention":5846,"totalTrials":94,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5865,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5858,"activeCount":98},[],{"trials":5860,"activeCount":98},[5861],{"nctId":5838,"briefTitle":5839,"status":148,"phases":5862,"completion":5841,"start":5842,"enrollment":5843,"conditions":5863,"interventions":5864},[86],[116],[5831,5846],{"trials":5866,"activeCount":98},[],{"trials":5868,"activeCount":98},[],{"trials":5870,"activeCount":98},[],{"trials":5872,"activeCount":98},[],{"intervention":5874,"totalTrials":94,"cells":5875},"NNC0361-0041",{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5890,"PHASE3":5892,"PHASE4":5894,"NA":5896},{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[5880],{"nctId":5881,"briefTitle":5882,"status":148,"phases":5883,"primaryCompletion":5884,"completion":5885,"start":5886,"enrollment":4673,"conditions":5887,"interventions":5889},"NCT04279613","A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041",[86],"2023-08-31","2024-04-24","2020-11-23",[5888],"Type I Diabetes",[5874],{"trials":5891,"activeCount":98},[],{"trials":5893,"activeCount":98},[],{"trials":5895,"activeCount":98},[],{"trials":5897,"activeCount":98},[],{"intervention":5899,"totalTrials":94,"cells":5900},"GCSF Mobilized Allogeneic PBSC Cultured w\u002FCytokines; Transduced w\u002FRV",{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5913,"PHASE3":5915,"PHASE4":5917,"NA":5919},{"trials":5902,"activeCount":98},[],{"trials":5904,"activeCount":98},[5905],{"nctId":5906,"briefTitle":5907,"status":148,"phases":5908,"completion":1151,"start":5909,"enrollment":256,"conditions":5910,"interventions":5912},"NCT00005785","Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer",[86],"1999-09",[5911,5129],"Hematologic Neoplasm",[5899],{"trials":5914,"activeCount":98},[],{"trials":5916,"activeCount":98},[],{"trials":5918,"activeCount":98},[],{"trials":5920,"activeCount":98},[],{"intervention":5922,"totalTrials":94,"cells":5923},"Avandia administration for 6-12 weeks",{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5934,"PHASE3":5936,"PHASE4":5938,"NA":5940},{"trials":5925,"activeCount":98},[],{"trials":5927,"activeCount":98},[5928],{"nctId":5929,"briefTitle":5930,"status":148,"phases":5931,"completion":3674,"start":5909,"conditions":5932,"interventions":5933},"NCT00006185","Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome",[86],[1154,34,232],[5922],{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[],{"trials":5939,"activeCount":98},[],{"trials":5941,"activeCount":98},[],{"intervention":5943,"totalTrials":94,"cells":5944},"EBV-specific autologous CTL",{"EARLY_PHASE1":5945,"PHASE1":5947,"PHASE2":5956,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5946,"activeCount":98},[],{"trials":5948,"activeCount":98},[5949],{"nctId":5950,"briefTitle":5951,"status":148,"phases":5952,"completion":2097,"start":1623,"enrollment":571,"conditions":5953,"interventions":5955},"NCT00063648","Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant",[86],[2423,5954],"Lymphoproliferative Disorders",[5943],{"trials":5957,"activeCount":98},[],{"trials":5959,"activeCount":98},[],{"trials":5961,"activeCount":98},[],{"trials":5963,"activeCount":98},[],{"intervention":5965,"totalTrials":94,"cells":5966},"[c11] raclopride",{"EARLY_PHASE1":5967,"PHASE1":5979,"PHASE2":5981,"PHASE3":5983,"PHASE4":5985,"NA":5987},{"trials":5968,"activeCount":98},[5969],{"nctId":5970,"briefTitle":5971,"status":148,"phases":5972,"primaryCompletion":5973,"completion":5974,"start":5975,"enrollment":4954,"conditions":5976,"interventions":5977},"NCT03648892","Brain Dopamine Function in Human Obesity",[85],"2022-03-31","2023-02-17","2018-09-21",[15,21,29],[5965,5978],"[18F]fallypride",{"trials":5980,"activeCount":98},[],{"trials":5982,"activeCount":98},[],{"trials":5984,"activeCount":98},[],{"trials":5986,"activeCount":98},[],{"trials":5988,"activeCount":98},[],{"intervention":5978,"totalTrials":94,"cells":5990},{"EARLY_PHASE1":5991,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5992,"activeCount":98},[5993],{"nctId":5970,"briefTitle":5971,"status":148,"phases":5994,"primaryCompletion":5973,"completion":5974,"start":5975,"enrollment":4954,"conditions":5995,"interventions":5996},[85],[15,21,29],[5965,5978],{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[],{"trials":6002,"activeCount":98},[],{"trials":6004,"activeCount":98},[],{"trials":6006,"activeCount":98},[],{"intervention":6008,"totalTrials":94,"cells":6009},"n-aceylcysteine",{"EARLY_PHASE1":6010,"PHASE1":6020,"PHASE2":6022,"PHASE3":6024,"PHASE4":6026,"NA":6028},{"trials":6011,"activeCount":98},[6012],{"nctId":6013,"briefTitle":6014,"status":148,"phases":6015,"primaryCompletion":6016,"completion":6016,"start":1360,"enrollment":6017,"conditions":6018,"interventions":6019},"NCT00609102","Antioxidant Treatment of Type 2 Diabetes",[85],"2013-09",44,[32],[6008],{"trials":6021,"activeCount":98},[],{"trials":6023,"activeCount":98},[],{"trials":6025,"activeCount":98},[],{"trials":6027,"activeCount":98},[],{"trials":6029,"activeCount":98},[],{"intervention":6031,"totalTrials":94,"cells":6032},"caffeine administration",{"EARLY_PHASE1":6033,"PHASE1":6042,"PHASE2":6044,"PHASE3":6046,"PHASE4":6048,"NA":6050},{"trials":6034,"activeCount":98},[6035],{"nctId":6036,"briefTitle":6037,"status":148,"phases":6038,"completion":1511,"start":6039,"enrollment":1859,"conditions":6040,"interventions":6041},"NCT00432887","Experimental Studies of the Effects of Caffeine on Glucose Regulation",[85],"2004-07",[27],[6031],{"trials":6043,"activeCount":98},[],{"trials":6045,"activeCount":98},[],{"trials":6047,"activeCount":98},[],{"trials":6049,"activeCount":98},[],{"trials":6051,"activeCount":98},[],{"intervention":2172,"totalTrials":2613,"cells":6053},{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6058,"PHASE3":6079,"PHASE4":6113,"NA":6115},{"trials":6055,"activeCount":98},[],{"trials":6057,"activeCount":98},[],{"trials":6059,"activeCount":98},[6060,6064,6071],{"nctId":3908,"briefTitle":3909,"status":148,"phases":6061,"primaryCompletion":3911,"completion":3911,"start":3912,"enrollment":170,"conditions":6062,"interventions":6063},[86,87],[32],[3899,2172],{"nctId":6065,"briefTitle":6066,"status":148,"phases":6067,"primaryCompletion":6068,"completion":6068,"start":1519,"enrollment":1436,"conditions":6069,"interventions":6070},"NCT00063232","Treating Nonalcoholic Steatohepatitis (NASH) With Metformin",[87],"2008-03",[3704],[2172],{"nctId":6072,"briefTitle":6073,"status":148,"phases":6074,"primaryCompletion":6075,"completion":6075,"start":6076,"enrollment":1067,"conditions":6077,"interventions":6078},"NCT04209075","Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)",[87],"2021-07-15","2020-03-10",[18],[2172],{"trials":6080,"activeCount":98},[6081,6088,6098,6102],{"nctId":6082,"briefTitle":6083,"status":148,"phases":6084,"primaryCompletion":6085,"completion":2261,"start":1137,"enrollment":2727,"conditions":6086,"interventions":6087},"NCT00063635","Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)",[88],"2009-09",[4026],[2172],{"nctId":6089,"briefTitle":6090,"status":148,"phases":6091,"primaryCompletion":6092,"completion":6092,"start":1693,"enrollment":6093,"conditions":6094,"interventions":6097},"NCT00004992","Diabetes Prevention Program",[88],"2001-04",3234,[6095,6096],"Diabetes Mellitus, Non-Insulin-Dependent","Glucose Intolerance",[2172],{"nctId":2162,"briefTitle":2163,"status":148,"phases":6099,"primaryCompletion":2165,"completion":2166,"start":2167,"enrollment":2168,"conditions":6100,"interventions":6101},[88],[2170],[2172,2151],{"nctId":6103,"briefTitle":6104,"status":1788,"phases":6105,"primaryCompletion":6106,"completion":6107,"start":1025,"enrollment":6108,"conditions":6109,"interventions":6112},"NCT00038727","Diabetes Prevention Program Outcomes Study",[88],"2024-10","2025-01",2779,[24,6110,6111],"Cancer","CVD",[2172],{"trials":6114,"activeCount":98},[],{"trials":6116,"activeCount":98},[6117],{"nctId":6118,"briefTitle":6119,"status":148,"phases":6120,"start":1999,"enrollment":6121,"conditions":6122,"interventions":6123},"NCT00445627","Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus",[],82,[15,29,27],[2172,3063],{"intervention":6125,"totalTrials":122,"cells":6126},"Pioglitazone",{"EARLY_PHASE1":6127,"PHASE1":6129,"PHASE2":6131,"PHASE3":6139,"PHASE4":6149,"NA":6155},{"trials":6128,"activeCount":98},[],{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[6133],{"nctId":6134,"briefTitle":6135,"status":148,"phases":6136,"completion":2284,"start":1692,"enrollment":256,"conditions":6137,"interventions":6138},"NCT00013598","Treatment of Nonalcoholic Steatohepatitis With Pioglitazone",[87],[4026,3792],[6125],{"trials":6140,"activeCount":98},[6141],{"nctId":6142,"briefTitle":6143,"status":148,"phases":6144,"primaryCompletion":3537,"completion":6085,"start":2858,"enrollment":6145,"conditions":6146,"interventions":6148},"NCT00063622","Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)",[88],247,[6147],"Liver Diseases",[6125],{"trials":6150,"activeCount":98},[6151],{"nctId":1254,"briefTitle":1255,"status":148,"phases":6152,"completion":1257,"start":1258,"enrollment":304,"conditions":6153,"interventions":6154},[89],[232,1260],[1262,1241],{"trials":6156,"activeCount":98},[6157,6165],{"nctId":6158,"briefTitle":6159,"status":148,"phases":6160,"primaryCompletion":2331,"completion":478,"start":2858,"enrollment":6017,"conditions":6161,"interventions":6164},"NCT00639457","Exercise and Pioglitazone for HIV-Metabolic Syndromes",[90],[1154,32,15,6162,6163,1935,34],"HIV","AIDS",[6125],{"nctId":6166,"briefTitle":6167,"status":148,"phases":6168,"primaryCompletion":6169,"completion":411,"start":1137,"enrollment":170,"conditions":6170,"interventions":6173},"NCT00656851","Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome",[90],"2009-08",[1154,1935,232,6171,6172],"HIV Lipodystrophy","The Metabolic Syndrome",[6125],{"intervention":6175,"totalTrials":279,"cells":6176},"Testosterone",{"EARLY_PHASE1":6177,"PHASE1":6179,"PHASE2":6181,"PHASE3":6191,"PHASE4":6193,"NA":6195},{"trials":6178,"activeCount":98},[],{"trials":6180,"activeCount":98},[],{"trials":6182,"activeCount":98},[6183],{"nctId":6184,"briefTitle":6185,"status":148,"phases":6186,"completion":291,"start":6187,"conditions":6188,"interventions":6190},"NCT00006158","AIDS Wasting in Women: Anabolic Effects of Testosterone",[87],"1998-09",[6189],"AIDS Wasting Syndrome",[6175],{"trials":6192,"activeCount":98},[],{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[6197,6209],{"nctId":6198,"briefTitle":6199,"status":6200,"phases":6201,"primaryCompletion":2165,"completion":3058,"start":6202,"enrollment":9,"conditions":6203,"interventions":6205},"NCT00433173","Insulin Sensitivity in Men With the Metabolic Syndrome","SUSPENDED",[90],"2006-05",[6204],"Metabolic Syndrome",[6206,6207,6208],"testosterone","anastrozole","goserelin acetate implant",{"nctId":6210,"briefTitle":6211,"status":1788,"phases":6212,"primaryCompletion":6213,"completion":1095,"start":6214,"enrollment":4438,"conditions":6215,"interventions":6216},"NCT00983554","Metabolic Effects of Steroids in Obese Men",[90],"2009-05","2005-06",[15,232],[6217,6175,6218,6219],"Anastrazole","Dutasteride","GnRH antagonist",{"intervention":6219,"totalTrials":164,"cells":6221},{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6228,"PHASE4":6230,"NA":6232},{"trials":6223,"activeCount":98},[],{"trials":6225,"activeCount":98},[],{"trials":6227,"activeCount":98},[],{"trials":6229,"activeCount":98},[],{"trials":6231,"activeCount":98},[],{"trials":6233,"activeCount":98},[6234,6238],{"nctId":6210,"briefTitle":6211,"status":1788,"phases":6235,"primaryCompletion":6213,"completion":1095,"start":6214,"enrollment":4438,"conditions":6236,"interventions":6237},[90],[15,232],[6217,6175,6218,6219],{"nctId":6239,"briefTitle":6240,"status":148,"phases":6241,"primaryCompletion":1857,"completion":1857,"start":6242,"enrollment":1176,"conditions":6243,"interventions":6244},"NCT00470990","Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men",[90],"2002-10",[1628],[6219],{"intervention":3063,"totalTrials":164,"cells":6246},{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6251,"PHASE3":6257,"PHASE4":6259,"NA":6261},{"trials":6248,"activeCount":98},[],{"trials":6250,"activeCount":98},[],{"trials":6252,"activeCount":98},[6253],{"nctId":3055,"briefTitle":3056,"status":447,"phases":6254,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":981,"conditions":6255,"interventions":6256},[87],[3050,3061],[3063,3064,3037,3065,3066],{"trials":6258,"activeCount":98},[],{"trials":6260,"activeCount":98},[],{"trials":6262,"activeCount":98},[6263],{"nctId":6118,"briefTitle":6119,"status":148,"phases":6264,"start":1999,"enrollment":6121,"conditions":6265,"interventions":6266},[],[15,29,27],[2172,3063],{"intervention":6207,"totalTrials":94,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6275,"PHASE4":6277,"NA":6279},{"trials":6270,"activeCount":98},[],{"trials":6272,"activeCount":98},[],{"trials":6274,"activeCount":98},[],{"trials":6276,"activeCount":98},[],{"trials":6278,"activeCount":98},[],{"trials":6280,"activeCount":98},[6281],{"nctId":6198,"briefTitle":6199,"status":6200,"phases":6282,"primaryCompletion":2165,"completion":3058,"start":6202,"enrollment":9,"conditions":6283,"interventions":6284},[90],[6204],[6206,6207,6208],{"intervention":6208,"totalTrials":94,"cells":6286},{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6291,"PHASE3":6293,"PHASE4":6295,"NA":6297},{"trials":6288,"activeCount":98},[],{"trials":6290,"activeCount":98},[],{"trials":6292,"activeCount":98},[],{"trials":6294,"activeCount":98},[],{"trials":6296,"activeCount":98},[],{"trials":6298,"activeCount":98},[6299],{"nctId":6198,"briefTitle":6199,"status":6200,"phases":6300,"primaryCompletion":2165,"completion":3058,"start":6202,"enrollment":9,"conditions":6301,"interventions":6302},[90],[6204],[6206,6207,6208],{"intervention":6304,"totalTrials":94,"cells":6305},"acetominophen, sulfer amino acids; cysteine and methionine",{"EARLY_PHASE1":6306,"PHASE1":6308,"PHASE2":6310,"PHASE3":6312,"PHASE4":6314,"NA":6316},{"trials":6307,"activeCount":98},[],{"trials":6309,"activeCount":98},[],{"trials":6311,"activeCount":98},[],{"trials":6313,"activeCount":98},[],{"trials":6315,"activeCount":98},[],{"trials":6317,"activeCount":98},[6318],{"nctId":6319,"briefTitle":6320,"status":148,"phases":6321,"completion":2701,"start":2858,"enrollment":2421,"conditions":6322,"interventions":6324},"NCT00253773","Metabolic Effects of Chemical Interactions in Toxicity",[90],[6323],"Oxidative Stress",[6304],{"intervention":6217,"totalTrials":94,"cells":6326},{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6333,"PHASE4":6335,"NA":6337},{"trials":6328,"activeCount":98},[],{"trials":6330,"activeCount":98},[],{"trials":6332,"activeCount":98},[],{"trials":6334,"activeCount":98},[],{"trials":6336,"activeCount":98},[],{"trials":6338,"activeCount":98},[6339],{"nctId":6210,"briefTitle":6211,"status":1788,"phases":6340,"primaryCompletion":6213,"completion":1095,"start":6214,"enrollment":4438,"conditions":6341,"interventions":6342},[90],[15,232],[6217,6175,6218,6219],{"intervention":6218,"totalTrials":94,"cells":6344},{"EARLY_PHASE1":6345,"PHASE1":6347,"PHASE2":6349,"PHASE3":6351,"PHASE4":6353,"NA":6355},{"trials":6346,"activeCount":98},[],{"trials":6348,"activeCount":98},[],{"trials":6350,"activeCount":98},[],{"trials":6352,"activeCount":98},[],{"trials":6354,"activeCount":98},[],{"trials":6356,"activeCount":98},[6357],{"nctId":6210,"briefTitle":6211,"status":1788,"phases":6358,"primaryCompletion":6213,"completion":1095,"start":6214,"enrollment":4438,"conditions":6359,"interventions":6360},[90],[15,232],[6217,6175,6218,6219],{"intervention":6362,"totalTrials":94,"cells":6363},"Fluoxetine",{"EARLY_PHASE1":6364,"PHASE1":6366,"PHASE2":6368,"PHASE3":6370,"PHASE4":6372,"NA":6374},{"trials":6365,"activeCount":98},[],{"trials":6367,"activeCount":98},[],{"trials":6369,"activeCount":98},[],{"trials":6371,"activeCount":98},[],{"trials":6373,"activeCount":98},[],{"trials":6375,"activeCount":98},[6376],{"nctId":6377,"briefTitle":6378,"status":148,"phases":6379,"completion":1114,"start":1190,"conditions":6380,"interventions":6382},"NCT00009178","Treatment of Bulimia Nervosa in a Primary Care Setting",[90],[6381],"Bulimia Nervosa",[6362],{"intervention":6384,"totalTrials":94,"cells":6385},"nandrolone decanoate",{"EARLY_PHASE1":6386,"PHASE1":6388,"PHASE2":6390,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6387,"activeCount":98},[],{"trials":6389,"activeCount":98},[],{"trials":6391,"activeCount":98},[],{"trials":6393,"activeCount":98},[],{"trials":6395,"activeCount":98},[],{"trials":6397,"activeCount":98},[6398],{"nctId":6399,"briefTitle":6400,"status":148,"phases":6401,"completion":1189,"start":292,"enrollment":347,"conditions":6402,"interventions":6405},"NCT00250536","Anabolic Steroids and Exercise in Hemodialysis Patients",[90],[6403,6404],"End-Stage Renal Disease","Muscle Weakness",[6384],{"intervention":6407,"totalTrials":94,"cells":6408},"Pentagastrin",{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6413,"PHASE3":6415,"PHASE4":6417,"NA":6419},{"trials":6410,"activeCount":98},[],{"trials":6412,"activeCount":98},[],{"trials":6414,"activeCount":98},[],{"trials":6416,"activeCount":98},[],{"trials":6418,"activeCount":98},[],{"trials":6420,"activeCount":98},[6421],{"nctId":6422,"briefTitle":6423,"status":148,"phases":6424,"start":6425,"enrollment":347,"conditions":6426,"interventions":6428},"NCT00702533","A New Method for Determining Gastric Acid Output Using a Wireless Capsule",[],"2008-06-18",[6427],"Gastric Acid Secretory Disorders",[6407],{"intervention":6430,"totalTrials":94,"cells":6431},"dual cholate",{"EARLY_PHASE1":6432,"PHASE1":6434,"PHASE2":6436,"PHASE3":6438,"PHASE4":6440,"NA":6442},{"trials":6433,"activeCount":98},[],{"trials":6435,"activeCount":98},[],{"trials":6437,"activeCount":98},[],{"trials":6439,"activeCount":98},[],{"trials":6441,"activeCount":98},[],{"trials":6443,"activeCount":98},[6444],{"nctId":6445,"briefTitle":6446,"status":148,"phases":6447,"primaryCompletion":6448,"completion":6449,"start":6450,"enrollment":256,"conditions":6451,"interventions":6452},"NCT02400216","Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis",[],"2017-02-24","2017-04-25","2015-05-29",[540],[6430],{"intervention":6454,"totalTrials":94,"cells":6455},"L-Arginine Supplementation",{"EARLY_PHASE1":6456,"PHASE1":6458,"PHASE2":6460,"PHASE3":6462,"PHASE4":6464,"NA":6466},{"trials":6457,"activeCount":98},[],{"trials":6459,"activeCount":98},[],{"trials":6461,"activeCount":98},[],{"trials":6463,"activeCount":98},[],{"trials":6465,"activeCount":98},[],{"trials":6467,"activeCount":98},[6468],{"nctId":6469,"briefTitle":6470,"status":148,"phases":6471,"completion":6472,"start":2678,"enrollment":2995,"conditions":6473,"interventions":6475},"NCT00275158","Glomerular Injury of Preeclampsia",[90],"2003-12",[6474],"Pre-Eclampsia",[6454],{"intervention":6477,"totalTrials":94,"cells":6478},"growth hormone administration for 6 months",{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6485,"PHASE4":6487,"NA":6489},{"trials":6480,"activeCount":98},[],{"trials":6482,"activeCount":98},[],{"trials":6484,"activeCount":98},[],{"trials":6486,"activeCount":98},[],{"trials":6488,"activeCount":98},[],{"trials":6490,"activeCount":98},[6491],{"nctId":6492,"briefTitle":6493,"status":148,"phases":6494,"primaryCompletion":478,"completion":478,"start":1137,"enrollment":6495,"conditions":6496,"interventions":6498},"NCT00149708","Consequence of Lifetime Isolated Growth Hormone Deficiency",[90],400,[6497],"Growth Hormone Deficiency",[6477],{"intervention":6500,"totalTrials":94,"cells":6501},"Sibutramine",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6510,"NA":6512},{"trials":6503,"activeCount":98},[],{"trials":6505,"activeCount":98},[],{"trials":6507,"activeCount":98},[],{"trials":6509,"activeCount":98},[],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[6514],{"nctId":6515,"briefTitle":6516,"status":148,"phases":6517,"completion":2909,"enrollment":1027,"conditions":6518,"interventions":6521},"NCT00212173","Adolescent Weight Management Study",[90],[6519,6520],"Protocol #1:Behavioral Therapy + Placebo or Sibutramine","Protocol #2: Behavioral Therapy + Meal Replacement or Conventional Food",[6500],{"intervention":6523,"totalTrials":94,"cells":6524},"calcitriol",{"EARLY_PHASE1":6525,"PHASE1":6527,"PHASE2":6529,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6526,"activeCount":98},[],{"trials":6528,"activeCount":98},[],{"trials":6530,"activeCount":98},[],{"trials":6532,"activeCount":98},[],{"trials":6534,"activeCount":98},[],{"trials":6536,"activeCount":98},[6537],{"nctId":6538,"briefTitle":6539,"status":476,"phases":6540,"start":3515,"enrollment":98,"conditions":6541,"interventions":6543},"NCT00004468","Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis",[90],[6542],"Psoriasis",[6523],{"intervention":6545,"totalTrials":94,"cells":6546},"dietary amino acids; cysteine and methionine",{"EARLY_PHASE1":6547,"PHASE1":6549,"PHASE2":6551,"PHASE3":6553,"PHASE4":6555,"NA":6557},{"trials":6548,"activeCount":98},[],{"trials":6550,"activeCount":98},[],{"trials":6552,"activeCount":98},[],{"trials":6554,"activeCount":98},[],{"trials":6556,"activeCount":98},[],{"trials":6558,"activeCount":98},[6559],{"nctId":6560,"briefTitle":6561,"status":148,"phases":6562,"completion":1511,"start":6563,"enrollment":2421,"conditions":6564,"interventions":6566},"NCT00253760","Metabolic Analysis in Human Sulfur Amino Acid Deficiency",[90],"2004-02",[6323,18,6565],"Heart Diseases",[6545],{"intervention":6568,"totalTrials":94,"cells":6569},"Diazepam",{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6574,"PHASE3":6576,"PHASE4":6578,"NA":6580},{"trials":6571,"activeCount":98},[],{"trials":6573,"activeCount":98},[],{"trials":6575,"activeCount":98},[],{"trials":6577,"activeCount":98},[],{"trials":6579,"activeCount":98},[],{"trials":6581,"activeCount":98},[6582],{"nctId":6583,"briefTitle":6584,"status":148,"phases":6585,"completion":2637,"start":5909,"enrollment":6586,"conditions":6587,"interventions":6588},"NCT00127257","Biofeedback for Dyssynergic Constipation",[90],117,[1697],[6568],{"intervention":6590,"totalTrials":94,"cells":6591},"General anesthesia with nitrous oxide",{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6598,"PHASE4":6600,"NA":6602},{"trials":6593,"activeCount":98},[],{"trials":6595,"activeCount":98},[],{"trials":6597,"activeCount":98},[],{"trials":6599,"activeCount":98},[],{"trials":6601,"activeCount":98},[],{"trials":6603,"activeCount":98},[6604],{"nctId":6605,"briefTitle":6606,"status":148,"phases":6607,"primaryCompletion":994,"completion":994,"start":6608,"enrollment":6609,"conditions":6610,"interventions":6613},"NCT00212147","Interaction of Cobalamin Status With Nitrous Oxide in Relation to Postoperative Cognitive Changes in the Elderly",[90],"2003-09",444,[6611,6612],"Avitaminosis","Delirium, Dementia, Amnestic, Cognitive Disorders",[6590,6614],"General anesthesia without nitrous oxide",{"intervention":6614,"totalTrials":94,"cells":6616},{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6618,"activeCount":98},[],{"trials":6620,"activeCount":98},[],{"trials":6622,"activeCount":98},[],{"trials":6624,"activeCount":98},[],{"trials":6626,"activeCount":98},[],{"trials":6628,"activeCount":98},[6629],{"nctId":6605,"briefTitle":6606,"status":148,"phases":6630,"primaryCompletion":994,"completion":994,"start":6608,"enrollment":6609,"conditions":6631,"interventions":6632},[90],[6611,6612],[6590,6614],{"intervention":6634,"totalTrials":94,"cells":6635},"ritonavir, lopinavir\u002Fritonavir, atazanavir\u002Fritonavir, efavirenz",{"EARLY_PHASE1":6636,"PHASE1":6638,"PHASE2":6640,"PHASE3":6642,"PHASE4":6644,"NA":6646},{"trials":6637,"activeCount":98},[],{"trials":6639,"activeCount":98},[],{"trials":6641,"activeCount":98},[],{"trials":6643,"activeCount":98},[],{"trials":6645,"activeCount":98},[],{"trials":6647,"activeCount":98},[6648],{"nctId":6649,"briefTitle":6650,"status":1788,"phases":6651,"primaryCompletion":6652,"completion":6652,"start":2284,"enrollment":230,"conditions":6653,"interventions":6654},"NCT00525239","HIV Antiretroviral Drugs and Metabolism",[90],"2010-12",[1154],[6634],{"intervention":6656,"totalTrials":94,"cells":6657},"HBIG, Epivir, Hepsera",{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6662,"PHASE3":6664,"PHASE4":6666,"NA":6668},{"trials":6659,"activeCount":98},[],{"trials":6661,"activeCount":98},[],{"trials":6663,"activeCount":98},[],{"trials":6665,"activeCount":98},[],{"trials":6667,"activeCount":98},[],{"trials":6669,"activeCount":98},[6670],{"nctId":6671,"briefTitle":6672,"status":148,"phases":6673,"primaryCompletion":2701,"completion":2701,"start":1692,"enrollment":6674,"conditions":6675,"interventions":6677},"NCT00059267","Prevention of Recurrent Hepatitis B After Liver Transplantation",[],317,[1428,540,701,6676],"Hepatocellular Carcinoma",[6656],{"intervention":6679,"totalTrials":94,"cells":6680},"Corticosteroids",{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6687,"PHASE4":6689,"NA":6691},{"trials":6682,"activeCount":98},[],{"trials":6684,"activeCount":98},[],{"trials":6686,"activeCount":98},[],{"trials":6688,"activeCount":98},[],{"trials":6690,"activeCount":98},[],{"trials":6692,"activeCount":98},[6693],{"nctId":6694,"briefTitle":6695,"status":148,"phases":6696,"primaryCompletion":6697,"completion":6697,"start":1036,"enrollment":6698,"conditions":6699,"interventions":6700},"NCT00294684","A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy",[90],"2013-01",141,[5545],[6679],{"intervention":6702,"totalTrials":94,"cells":6703},"celecoxib",{"EARLY_PHASE1":6704,"PHASE1":6706,"PHASE2":6708,"PHASE3":6710,"PHASE4":6712,"NA":6714},{"trials":6705,"activeCount":98},[],{"trials":6707,"activeCount":98},[],{"trials":6709,"activeCount":98},[],{"trials":6711,"activeCount":98},[],{"trials":6713,"activeCount":98},[],{"trials":6715,"activeCount":98},[6716],{"nctId":6717,"briefTitle":6718,"status":447,"phases":6719,"completion":291,"start":1175,"enrollment":256,"conditions":6720,"interventions":6721},"NCT00065559","Treatment of Diabetic Nephropathy",[90],[1384],[6702],{"intervention":6723,"totalTrials":94,"cells":6724},"Potassium Chloride",{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6731,"PHASE4":6733,"NA":6735},{"trials":6726,"activeCount":98},[],{"trials":6728,"activeCount":98},[],{"trials":6730,"activeCount":98},[],{"trials":6732,"activeCount":98},[],{"trials":6734,"activeCount":98},[],{"trials":6736,"activeCount":98},[6737],{"nctId":6738,"briefTitle":6739,"status":447,"phases":6740,"completion":1257,"start":1858,"enrollment":6741,"conditions":6742,"interventions":6744},"NCT00224939","Pre-ESRD Syndrome in High Risk African Americans",[90],144,[6743],"Blood Pressure",[6723]]